Cover Page
Cover Page - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Jan. 24, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Transition Report | false | ||
Entity File Number | 001-03761 | ||
Entity Registrant Name | TEXAS INSTRUMENTS INCORPORATED | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 75-0289970 | ||
Entity Address, Address Line One | 12500 TI Boulevard | ||
Entity Address, City or Town | Dallas | ||
Entity Address, State or Province | TX | ||
Entity Address, Postal Zip Code | 75243 | ||
City Area Code | 214 | ||
Local Phone Number | 479-3773 | ||
Title of 12(b) Security | Common Stock, par value $1.00 | ||
Trading Symbol | TXN | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 140,429,302,063 | ||
Entity Common Stock, Shares Outstanding | 906,205,795 | ||
Documents Incorporated by Reference | Part III hereof incorporates information by reference to the Registrant’s proxy statement for the 2023 annual meeting of stockholders. | ||
Entity Central Index Key | 0000097476 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2022 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2022 | |
Auditor [Abstract] | |
Auditor Name | Ernst & Young LLP |
Auditor Firm ID | 42 |
Auditor Location | Dallas, Texas |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Revenue | $ 20,028 | $ 18,344 | $ 14,461 |
Cost of revenue (COR) | 6,257 | 5,968 | 5,192 |
Gross profit | 13,771 | 12,376 | 9,269 |
Research and development (R&D) | 1,670 | 1,554 | 1,530 |
Selling, general and administrative (SG&A) | 1,704 | 1,666 | 1,623 |
Acquisition charges | 0 | 142 | 198 |
Restructuring charges/other | 257 | 54 | 24 |
Operating profit | 10,140 | 8,960 | 5,894 |
Other income (expense), net (OI&E) | 106 | 143 | 313 |
Interest and debt expense | 214 | 184 | 190 |
Income before income taxes | 10,032 | 8,919 | 6,017 |
Provision for income taxes | 1,283 | 1,150 | 422 |
Net income | $ 8,749 | $ 7,769 | $ 5,595 |
Earnings per common share (EPS): | |||
Basic (in dollars per share) | $ 9.51 | $ 8.38 | $ 6.05 |
Diluted (in dollars per share) | $ 9.41 | $ 8.26 | $ 5.97 |
Average shares outstanding: | |||
Basic (in shares) | 916 | 923 | 921 |
Diluted (in shares) | 926 | 936 | 933 |
Diluted EPS: | |||
Net income | $ 8,749 | $ 7,769 | $ 5,595 |
Income allocated to RSUs | (39) | (33) | (27) |
Income allocated to common stock for diluted EPS | $ 8,710 | $ 7,736 | $ 5,568 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Net income | $ 8,749 | $ 7,769 | $ 5,595 |
Net actuarial losses of defined benefit plans: | |||
Adjustments, net of tax effect of $48, ($56) and $3 | (155) | 175 | (41) |
Recognized within net income, net of tax effect of ($17), ($8) and ($9) | 61 | 29 | 29 |
Prior service cost of defined benefit plans: | |||
Recognized within net income, net of tax effect of $0, $0 and $0 | (1) | (1) | (1) |
Derivative instruments: | |||
Change in fair value, net of tax effect of $0, $0 and $0 | 1 | 0 | 0 |
Available-for-sale investments: | |||
Unrealized losses, net of tax effect of $1, $0 and $0 | (3) | 0 | 0 |
Other comprehensive income (loss), net of taxes | (97) | 203 | (13) |
Total comprehensive income | $ 8,652 | $ 7,972 | $ 5,582 |
Consolidated Statements of Co_2
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income | |||
Net actuarial losses of defined benefit plans adjustment, tax effect | $ 48 | $ (56) | $ 3 |
Net actuarial losses of defined benefit plans recognized within net income, tax effect | (17) | (8) | (9) |
Prior service cost of defined benefit plans recognized within net income, tax effect | 0 | 0 | 0 |
Derivative instruments change in fair value, tax effect | 0 | 0 | 0 |
Available-for-sale investments unrealized losses, tax effect | $ 1 | $ 0 | $ 0 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 3,050 | $ 4,631 |
Short-term investments | 6,017 | 5,108 |
Accounts receivable, net of allowances of ($13) and ($8) | 1,895 | 1,701 |
Raw materials | 353 | 245 |
Work in process | 1,546 | 1,067 |
Finished goods | 858 | 598 |
Inventories | 2,757 | 1,910 |
Prepaid expenses and other current assets | 302 | 335 |
Total current assets | 14,021 | 13,685 |
Property, plant and equipment at cost | 9,950 | 7,858 |
Accumulated depreciation | (3,074) | (2,717) |
Property, plant and equipment | 6,876 | 5,141 |
Goodwill | 4,362 | 4,362 |
Deferred tax assets | 473 | 263 |
Capitalized software licenses | 152 | 85 |
Overfunded retirement plans | 188 | 392 |
Other long-term assets | 1,135 | 748 |
Total assets | 27,207 | 24,676 |
Current liabilities: | ||
Current portion of long-term debt | 500 | 500 |
Accounts payable | 851 | 571 |
Accrued compensation | 799 | 775 |
Income taxes payable | 189 | 121 |
Accrued expenses and other liabilities | 646 | 602 |
Total current liabilities | 2,985 | 2,569 |
Long-term debt | 8,235 | 7,241 |
Underfunded retirement plans | 118 | 79 |
Deferred tax liabilities | 66 | 87 |
Other long-term liabilities | 1,226 | 1,367 |
Total liabilities | 12,630 | 11,343 |
Stockholders’ equity: | ||
Preferred stock, $25 par value. Shares authorized – 10; none issued | 0 | 0 |
Common stock, $1 par value. Shares authorized – 2,400; shares issued – 1,741 | 1,741 | 1,741 |
Paid-in capital | 2,951 | 2,630 |
Retained earnings | 50,353 | 45,919 |
Treasury common stock at cost Shares: 2022 - 835 ; 2021 - 817 | (40,214) | (36,800) |
Accumulated other comprehensive income (loss), net of taxes (AOCI) | (254) | (157) |
Total stockholders’ equity | 14,577 | 13,333 |
Total liabilities and stockholders’ equity | $ 27,207 | $ 24,676 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Allowance for doubtful accounts receivable, current | $ (13) | $ (8) |
Stockholders' equity: | ||
Preferred stock, par value (in dollars per share) | $ 25 | $ 25 |
Preferred stock, shares authorized (in shares) | 10 | 10 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 1 | $ 1 |
Common stock, shares authorized (in shares) | 2,400 | 2,400 |
Common stock, shares issued (in shares) | 1,741 | 1,741 |
Treasury stock (in shares) | 835 | 817 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Cash flows from operating activities | ||||
Net income | $ 8,749 | $ 7,769 | $ 5,595 | |
Adjustments to net income: | ||||
Depreciation | 925 | 755 | 733 | |
Amortization of acquisition-related intangibles | 0 | 142 | 198 | |
Amortization of capitalized software | 54 | 57 | 61 | |
Stock compensation | 289 | 230 | 224 | |
Gains on sales of assets | (3) | (57) | (4) | |
Deferred taxes | (191) | 15 | (137) | |
Increase (decrease) from changes in: | ||||
Accounts receivable | (194) | (287) | (340) | |
Inventories | (847) | 45 | 46 | |
Prepaid expenses and other current assets | 6 | 57 | (79) | |
Accounts payable and accrued expenses | 106 | 33 | 63 | |
Accrued compensation | 22 | 7 | 63 | |
Income taxes payable | 94 | (20) | (181) | |
Changes in funded status of retirement plans | 114 | 62 | (9) | |
Other | (404) | (52) | (94) | |
Cash flows from operating activities | 8,720 | 8,756 | 6,139 | |
Cash flows from investing activities | ||||
Capital expenditures | (2,797) | (2,462) | (649) | |
Proceeds from asset sales | 3 | 75 | 4 | |
Purchases of short-term investments | (14,483) | (10,124) | (5,786) | |
Proceeds from short-term investments | 13,657 | 8,478 | 5,545 | |
Other | 37 | (62) | (36) | |
Cash flows from investing activities | (3,583) | (4,095) | (922) | |
Cash flows from financing activities | ||||
Proceeds from issuance of long-term debt | 1,494 | 1,495 | 1,498 | |
Repayment of debt | (500) | (550) | (500) | |
Dividends paid | (4,297) | (3,886) | (3,426) | |
Stock repurchases | (3,615) | (527) | (2,553) | |
Proceeds from common stock transactions | [1] | 241 | 377 | 470 |
Other | (41) | (46) | (36) | |
Cash flows from financing activities | (6,718) | (3,137) | (4,547) | |
Net change in cash and cash equivalents | (1,581) | 1,524 | 670 | |
Cash and cash equivalents at beginning of period | 4,631 | 3,107 | 2,437 | |
Cash and cash equivalents at end of period | $ 3,050 | $ 4,631 | $ 3,107 | |
[1]Net of taxes paid for employee shares withheld of $50 million, $53 million and $53 million in 2022, 2021 and 2020, respectively. |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions | Total | Common Stock | Paid-in Capital | Retained Earnings | Treasury Common Stock | AOCI |
Balance, beginning balance at Dec. 31, 2019 | $ 1,741 | $ 2,110 | $ 39,898 | $ (34,495) | $ (347) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | $ 5,595 | 5,595 | ||||
Dividends declared and paid | (3,426) | |||||
Common stock issued for stock-based awards | 0 | 470 | ||||
Stock repurchases | (2,553) | |||||
Stock compensation | 224 | |||||
Other comprehensive income (loss), net of taxes | (13) | (13) | ||||
Dividend equivalents on RSUs | (16) | |||||
Other | (1) | 0 | ||||
Balance, ending balance at Dec. 31, 2020 | 1,741 | 2,333 | 42,051 | (36,578) | (360) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 7,769 | 7,769 | ||||
Dividends declared and paid | (3,886) | |||||
Common stock issued for stock-based awards | 67 | 310 | ||||
Stock repurchases | (532) | |||||
Stock compensation | 230 | |||||
Other comprehensive income (loss), net of taxes | 203 | 203 | ||||
Dividend equivalents on RSUs | (15) | |||||
Balance, ending balance at Dec. 31, 2021 | 13,333 | 1,741 | 2,630 | 45,919 | (36,800) | (157) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 8,749 | 8,749 | ||||
Dividends declared and paid | (4,297) | |||||
Common stock issued for stock-based awards | 35 | 206 | ||||
Stock repurchases | (3,620) | |||||
Stock compensation | 289 | |||||
Other comprehensive income (loss), net of taxes | (97) | (97) | ||||
Dividend equivalents on RSUs | (18) | |||||
Other | (3) | |||||
Balance, ending balance at Dec. 31, 2022 | $ 14,577 | $ 1,741 | $ 2,951 | $ 50,353 | $ (40,214) | $ (254) |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | |||
Cash dividends declared per common share (in dollars per share) | $ 4.69 | $ 4.21 | $ 3.72 |
Cash dividends paid per common share (in dollars per share) | $ 4.69 | $ 4.21 | $ 3.72 |
Description of Business, Includ
Description of Business, Including Segment and Geographic Area Information | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
Description of business, including segment and geographic area information | Description of business, including segment and geographic area information We design and manufacture semiconductors that we sell to electronics designers and manufacturers all over the world. We have two reportable segments, Analog and Embedded Processing, each of which represents groups of similar products that are combined on the basis of similar design and development requirements, product characteristics, manufacturing processes and distribution channels. Our segments also reflect how management allocates resources and measures results. • Analog semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. Analog semiconductors are also used to manage power in all electronic equipment by converting, distributing, storing, discharging, isolating and measuring electrical energy, whether the equipment is plugged into a wall or using a battery. Our Analog segment consists of two major product lines: Power and Signal Chain. • Embedded Processing products are the digital “brains” of many types of electronic equipment. They are designed to handle specific tasks and can be optimized for various combinations of performance, power and cost, depending on the application. We report the results of our remaining business activities in Other. Other includes operating segments that do not meet the quantitative thresholds for individually reportable segments and cannot be aggregated with other operating segments. Other includes DLP ® products, calculators and custom ASIC products. In Other, we also include items that are not used in evaluating the results of or in allocating resources to our segments. Examples of these items include acquisition, integration and restructuring charges (see Note 11); and certain corporate-level items, such as litigation expenses, environmental costs, insurance settlements, and gains and losses from other activities, including asset dispositions. We allocate the remainder of our expenses associated with corporate activities to our operating segments based on specific methodologies, such as percentage of operating expenses or headcount. Our centralized manufacturing and support organizations, such as facilities, procurement and logistics, provide support to our operating segments, including those in Other. Costs incurred by these organizations, including depreciation, are charged to the segments on a per-unit basis. Consequently, depreciation expense is not an independently identifiable component within the segments’ results and, therefore, is not provided. With the exception of goodwill, we do not identify or allocate assets by operating segment, nor does the chief operating decision maker evaluate operating segments using discrete asset information. We have no material intersegment revenue. The accounting policies of the segments are consistent with those described in the summary of significant accounting policies and practices. Segment information For Years Ended December 31, 2022 2021 2020 Revenue: Analog $ 15,359 $ 14,050 $ 10,886 Embedded Processing 3,261 3,049 2,570 Other 1,408 1,245 1,005 Total revenue $ 20,028 $ 18,344 $ 14,461 Operating profit: Analog $ 8,359 $ 7,393 $ 4,912 Embedded Processing 1,253 1,174 743 Other 528 393 239 Total operating profit $ 10,140 $ 8,960 $ 5,894 Geographic area information The following geographic information is based on product shipment destination, which does not reflect end demand by geography. For Years Ended December 31, 2022 2021 2020 Revenue: United States $ 2,267 11 % $ 1,906 10 % $ 1,547 11 % China (a) 9,844 49 9,998 55 7,881 54 Rest of Asia 2,633 13 2,187 12 1,660 11 Europe, Middle East and Africa 3,520 18 2,802 15 2,249 16 Japan 1,172 6 959 5 734 5 Rest of world 592 3 492 3 390 3 Total revenue $ 20,028 100 % $ 18,344 100 % $ 14,461 100 % (a) Revenue from products shipped into China includes shipments to customers that manufacture in China and then export end products to their customers around the world, as well as distributors that transship inventory through China to service other countries. The following additional geographic information includes our estimate for revenue based on the location of our end customers’ headquarters, providing a better representation of the geographic profile for where critical decisions are made. For Years Ended December 31, 2022 2021 2020 Revenue: United States $ 6,609 33 % $ 6,237 34 % $ 5,205 36 % China 4,807 24 4,586 25 3,326 23 Rest of Asia 2,003 10 2,018 11 1,591 11 Europe, Middle East and Africa (a) 4,807 24 3,852 21 3,037 21 Japan 1,602 8 1,468 8 1,157 8 Rest of world 200 1 183 1 145 1 Total revenue $ 20,028 100 % $ 18,344 100 % $ 14,461 100 % (a) Revenue from end customers headquartered in Germany was 11%, 9% and 9% of total revenue in 2022, 2021 and 2020, respectively. Property, plant and equipment by geographic area, based on physical location: December 31, 2022 2021 Property, plant and equipment: United States $ 5,134 $ 3,648 China 648 570 Rest of Asia 896 722 Europe, Middle East and Africa 44 47 Japan 121 139 Rest of world 33 15 Total property, plant and equipment $ 6,876 $ 5,141 Major customer |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies and Practices | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of presentation and significant accounting policies and practices | Basis of presentation and significant accounting policies and practices Basis of presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The basis of these financial statements is comparable for all periods presented herein. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. All dollar and share amounts in the financial statements and tables in these notes, except per-share amounts, are presented in millions unless otherwise indicated. We have reclassified certain amounts in the prior periods’ financial statements to conform to the 2022 presentation. The preparation of financial statements requires the use of estimates from which final results may vary. Significant accounting policies and practices Revenue recognition We generate revenue primarily from the sale of semiconductor products, either directly to a customer or to a distributor, and recognize revenue when control is transferred. Control is considered transferred when title and risk of loss pass, when the customer becomes obligated to pay and, where required, when the customer has accepted the products. This transfer generally occurs at a point in time upon shipment or delivery to the customer or distributor, depending upon the terms of the sales order. Payment for sales to customers and distributors is generally due on our standard commercial terms. For sales to distributors, payment is not contingent upon resale of the products. Revenue from sales of our products that are subject to inventory consignment agreements is recognized at a point in time, when the customer or distributor pulls product from consignment inventory that we store at designated locations. Delivery and transfer of control occur at that point, when title and risk of loss transfers and the customer or distributor becomes obligated to pay for the products pulled from inventory. Until the products are pulled for use or sale by the customer or distributor, we retain control over the products’ disposition, including the right to pull back or relocate the products. The revenue recognized is adjusted based on allowances, which are prepared on a portfolio basis using a most likely amount methodology based on analysis of historical data and contractual terms. These allowances, which are not material, generally include adjustments for pricing arrangements, product returns , incentives and credit losses. We recognize shipping fees received from customers, if any, in revenue. We include the related shipping and handling costs in cost of revenue. The majority of our customers pay these fees directly to third parties. Advertising costs We expense advertising and other promotional costs as incurred. This expense was $27 million, $27 million and $28 million in 2022, 2021 and 2020, respectively. Income taxes We account for income taxes using an asset and liability approach. We record the amount of taxes payable or refundable for the current year and the deferred tax assets and liabilities for future tax consequences related to events that have been recognized in the financial statements or tax returns. We record a valuation allowance when it is more likely than not that some or all of the deferred tax assets will not be realized. Other assessed taxes Some transactions require us to collect taxes such as sales, value-added and excise taxes from our customers. These transactions are presented in our Consolidated Statements of Income on a net (excluded from revenue) basis. Leases We determine if an arrangement is a lease at inception. Leases are included in other long-term assets, accrued expenses and other liabilities, and other long-term liabilities on our Consolidated Balance Sheets. Lease assets represent our right to use underlying assets for the lease term, and lease liabilities represent our obligations to make lease payments over the lease term. On the commencement date, leases are evaluated for classification, and assets and liabilities are recognized based on the present value of lease payments over the lease term. We use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. Operating lease expense is generally recognized on a straight-line basis over the lease term. Our lease values include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. We have agreements with lease and non-lease components, which are accounted for as a single lease component. Leases with an initial lease term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Earnings per share (EPS) We use the two-class method for calculating EPS because the restricted stock units (RSUs) we grant are participating securities containing non-forfeitable rights to receive dividend equivalents. Under the two-class method, a portion of net income is allocated to RSUs and excluded from the calculation of income allocated to common stock. Computation and reconciliation of earnings per common share are as follows: For Years Ended December 31, 2022 2021 2020 Net Income Shares EPS Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 8,749 $ 7,769 $ 5,595 Income allocated to RSUs (40) (33) (27) Income allocated to common stock $ 8,709 916 $ 9.51 $ 7,736 923 $ 8.38 $ 5,568 921 $ 6.05 Dilutive effect of stock compensation plans 10 13 12 Diluted EPS: Net income $ 8,749 $ 7,769 $ 5,595 Income allocated to RSUs (39) (33) (27) Income allocated to common stock $ 8,710 926 $ 9.41 $ 7,736 936 $ 8.26 $ 5,568 933 $ 5.97 Potentially dilutive securities representing 5 million, 3 million and 4 million shares of common stock that were outstanding in 2022, 2021 and 2020 respectively, were excluded from the computation of diluted earnings per common share during these periods because their effect would have been anti-dilutive. Investments We present investments on our Consolidated Balance Sheets as cash equivalents, short-term investments or other long-term assets. See Note 6 for additional information. • Cash equivalents and short-term investments – The primary objectives of our cash equivalent and short-term investment activities are to preserve capital and maintain liquidity while generating appropriate returns. We consider investments in available-for-sale debt securities with maturities of 90 days or less from the date of our investment to be cash equivalents. We consider investments in available-for-sale debt securities with maturities beyond 90 days from the date of our investment as being available for use in current operations and include them in short-term investments. • Other long-term assets – Long-term investments, which are included within other long-term assets on our Consolidated Balance Sheets, consist of mutual funds, venture capital funds and non-marketable securities. Inventories Inventories are stated at the lower of cost or estimated net realizable value. Cost is generally computed on a currently adjusted standard cost basis, which approximates cost on a first-in, first-out basis. Standard cost is based on the normal utilization of installed factory capacity. Cost associated with underutilization of capacity is expensed as incurred. Inventory held at consignment locations is included in our finished goods inventory. We review inventory quarterly for salability and obsolescence. A statistical allowance is provided for inventory considered unlikely to be sold. The statistical allowance is based on an analysis of historical disposal activity, historical customer shipments, as well as estimated future sales. A specific allowance for each material type will be carried if there is a significant event not captured by the statistical allowance. We write off inventory in the period in which disposal occurs. Government incentives Incentives provided by government entities are recognized when we have reasonable assurance that we will comply with the conditions of the incentive, if any, and the incentive will be received. Incentives related to the acquisition or construction of fixed assets are recognized as a reduction in the carrying amounts of the related assets and reduce depreciation expense over the useful lives of the assets. Incentives for specific operating activities are offset against the related expense in the period the expense is incurred. In August 2022, the U.S. government enacted the U.S. CHIPS and Science Act, which provides funding for manufacturing grants and research investments, and it establishes a 25% investment tax credit for certain investments in U.S. semiconductor manufacturing. As of December 31, 2022, we have recognized $395 million of receivables in other long-term assets Property, plant and equipment; acquisition-related intangibles; and other capitalized costs Property, plant and equipment are stated at cost and depreciated over their estimated useful lives using the straight-line method. Our cost basis includes certain assets acquired in business combinations that were initially recorded at fair value as of the date of acquisition. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining lease term or the estimated useful lives of the improvements. We amortize acquisition-related intangibles on a straight-line basis over the estimated economic life of the assets. Capitalized software licenses are generally amortized on a straight-line basis over the term of the license. Fully depreciated or amortized assets are written off against accumulated depreciation or amortization. Impairments of long-lived assets We regularly review whether facts or circumstances exist that indicate the carrying values of property, plant and equipment or other long-lived assets, including intangible assets, are impaired. We assess the recoverability of assets by comparing the projected undiscounted net cash flows associated with those assets to their respective carrying amounts. Any impairment charge is based on the excess of the carrying amount over the fair value of those assets. Fair value is determined by available market valuations, if applicable, or by discounted cash flows. Goodwill Goodwill is reviewed for impairment annually in the fourth quarter or more frequently if certain impairment indicators arise. We perform a qualitative assessment to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying value, including goodwill. If we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying value, or if we elect not to use the qualitative assessment, then we perform the quantitative goodwill impairment test. See Note 11 for additional information. Foreign currency The functional currency for our non-U.S. subsidiaries is the U.S. dollar. Accounts recorded in currencies other than the U.S. dollar are remeasured into the functional currency. Current assets (except inventories), deferred taxes, other long-term assets, current liabilities and long-term liabilities are remeasured at exchange rates in effect at the end of each reporting period. Property, plant and equipment with associated depreciation and inventories are valued at historical exchange rates. Revenue and expense accounts other than depreciation for each month are calculated at the appropriate daily rate of exchange. Currency exchange gains and losses from remeasurement are credited or charged to OI&E. Derivatives and hedging We use derivative financial instruments to manage exposure to foreign exchange risk. These instruments are primarily forward foreign currency exchange contracts, which are used as economic hedges to reduce the earnings impact that exchange rate fluctuations may have on our non-U.S. dollar net balance sheet exposures. Gains and losses from changes in the fair value of these forward foreign currency exchange contracts are credited or charged to OI&E. We do not apply hedge accounting to our foreign currency derivative instruments. We are exposed to variability in compensation charges related to certain deferred compensation obligations to employees. We use total return swaps to economically hedge this exposure and offset the related compensation expense, recognizing changes in the value of the swaps and the related deferred compensation liabilities in SG&A. In connection with the issuance of long-term debt, we may use financial derivatives such as treasury-rate lock agreements that are recognized in AOCI and amortized over the life of the related debt. The results of these derivative transactions were not material. We do not use derivatives for speculative or trading purposes. |
Stock Compensation
Stock Compensation | 12 Months Ended |
Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock compensation | Stock compensation We have stock options outstanding to participants under long-term incentive plans. The option price per share may not be less than the fair market value of our common stock on the date of the grant. The options have a 10-year term, generally vest ratably over four years and continue to vest after the option recipient retires. We also have RSUs outstanding to participants under long-term incentive plans. Each RSU represents the right to receive one share of TI common stock, issued on the vesting date, which is generally four years after the date of grant. RSUs continue to vest after the recipient retires. Holders of RSUs receive an annual cash payment equivalent to the dividends paid on our common stock. The fair value per share of RSUs is generally determined based on the closing price of our common stock on the date of grant. We have options and RSUs outstanding to non-employee directors under director compensation plans. The plans generally provide for annual grants of stock options and RSUs, a one-time grant of RSUs to each new non-employee director and the issuance of TI common stock upon the distribution of stock units credited to director deferred compensation accounts. We also have an employee stock purchase plan (ESPP) under which options are offered to all eligible employees in amounts based on a percentage of the employee’s compensation, subject to a cap. Under the plan, the option price per share is 85% of the fair market value on the exercise date. As of December 31, 2022, 32 million shares remain available for future issuance under this plan. Total stock compensation expense recognized is as follows: For Years Ended December 31, 2022 2021 2020 COR $ 34 $ 21 $ 21 R&D 90 67 68 SG&A 165 134 135 Restructuring charges/other — 8 — Total $ 289 $ 230 $ 224 These amounts include expenses related to non-qualified stock options, RSUs and stock options offered under our ESPP and are net of estimated forfeitures. We recognize compensation expense for non-qualified stock options and RSUs on a straight-line basis over the minimum service period required for vesting of the award, adjusting for estimated forfeitures based on historical activity. Awards issued to employees who are retirement eligible or nearing retirement eligibility are expensed on an accelerated basis. Options issued under our ESPP are expensed over a three-month period. As of December 31, 2022, total future compensation related to equity awards not yet recognized in our Consolidated Statements of Income was $440 million, which we expect to recognize over a weighted average period of 1.9 years. Fair value methods and assumptions We account for all awards granted under our various stock compensation plans at fair value. We estimate the fair values for non-qualified stock options using the Black-Scholes-Merton option-pricing model with the following weighted average assumptions: For Years Ended December 31, 2022 2021 2020 Weighted average grant date fair value, per share $ 39.94 $ 40.78 $ 25.55 Weighted average assumptions used: Expected volatility 29 % 32 % 26 % Expected lives (in years) 6.4 6.7 6.8 Risk-free interest rates 1.83 % 0.72 % 1.53 % Expected dividend yields 2.64 % 2.41 % 2.76 % We use market-based measures of implied volatility to determine expected volatility on all options granted. We determine expected lives of options based on the historical option exercise experience of our option holders using a rolling 10-year average. Expected dividend yields are based on the annualized approved quarterly dividend rate and the current market price of our common stock at the time of grant. No assumption for a future dividend rate change is included unless there is an approved plan to change the dividend in the near term. Long-term incentive and director compensation plans Stock option and RSU transactions under our long-term incentive and director compensation plans are as follows: Stock Options RSUs Shares Weighted Average Exercise Price per Share Shares Weighted Average Grant Date Fair Value per Share Outstanding grants, December 31, 2021 25 $ 91.58 4 $ 124.80 Granted 4 $ 174.60 2 $ 174.39 Stock options exercised/RSUs vested (4) $ 67.64 (1) $ 112.87 Outstanding grants, December 31, 2022 (a) 25 $ 105.75 5 $ 147.30 (a) Forfeited and expired shares were not material. For Years Ended December 31, 2022 2021 2020 Weighted average grant date fair value per share for RSUs $ 174.39 $ 176.08 $ 130.59 Total grant date fair value of shares vested for RSUs $ 121 $ 115 $ 110 Aggregate intrinsic value of options exercised $ 336 $ 611 $ 681 As of December 31, 2022, 32 million shares remain available for future issuance under these plans. Summarized information about stock options outstanding as of December 31, 2022, is as follows: Stock Options Outstanding Exercise Price Range Number Outstanding (Shares) Weighted Average Remaining Contractual Life (Years) $32.48 to $193.58 25 5.3 Options Fully Vested and Expected to Vest (a) Options Exercisable Options outstanding (shares) 25 17 Weighted average remaining contractual life (in years) 5.3 4.0 Weighted average exercise price per share $ 105.25 $ 81.56 Intrinsic value (billions) $ 1.54 $ 1.42 (a) Includes effects of expected forfeitures. Excluding the effects of expected forfeitures, the aggregate intrinsic value of stock options outstanding was $1.54 billion. Effect on shares outstanding and treasury shares Treasury shares were acquired in connection with the board-authorized stock repurchase program. As of December 31, 2022, $21.48 billion of stock repurchase authorizations remain, and no expiration date has been specified. Our practice is to issue shares of common stock from treasury shares upon exercise of stock options, distribution of director deferred compensation and vesting of RSUs. The following table reflects the changes in our treasury shares: For Years Ended December 31, 2022 2021 2020 Balance, January 1 817 821 809 Repurchases 22 3 23 Shares issued (4) (7) (11) Balance, December 31 835 817 821 The effects on cash flows are as follows: For Years Ended December 31, 2022 2021 2020 Proceeds from common stock transactions (a) $ 241 $ 377 $ 470 Tax benefit realized from stock compensation 110 175 195 (a) Net of taxes paid for employee shares withheld of $50 million, $53 million and $53 million in 2022, 2021 and 2020, respectively. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Income taxes Income before income taxes is comprised of the following components: For Years Ended December 31, 2022 2021 2020 U.S. $ 9,122 $ 7,998 $ 5,210 Non-U.S. 910 921 807 Total $ 10,032 $ 8,919 $ 6,017 Provision for income taxes is comprised of the following components: For Years Ended December 31, 2022 2021 2020 Current Deferred Total Current Deferred Total Current Deferred Total U.S. federal $ 1,235 $ (223) $ 1,012 $ 948 $ (23) $ 925 $ 357 $ (122) $ 235 Non-U.S. 212 32 244 169 38 207 192 (15) 177 U.S. state 27 — 27 18 — 18 10 — 10 Total $ 1,474 $ (191) $ 1,283 $ 1,135 $ 15 $ 1,150 $ 559 $ (137) $ 422 Principal reconciling items from the U.S. statutory income tax rate to the effective tax rate (provision for income taxes as a percentage of income before income taxes) are as follows: For Years Ended December 31, 2022 2021 2020 U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Foreign derived intangible income (7.0) (6.1) (6.1) R&D tax credit (0.9) (0.9) (1.3) Stock compensation (0.7) (1.5) (2.5) Changes in uncertain tax positions 0.1 (0.2) (4.0) Other 0.3 0.6 (0.1) Effective tax rate 12.8 % 12.9 % 7.0 % On August 16, 2022, the U.S. government enacted the Inflation Reduction Act, which introduces a new 15% corporate minimum tax based on adjusted financial statement income effective January 1, 2023, and provisions intended to mitigate climate change, including tax credit incentives for investments that reduce greenhouse gas emissions. Based on our current analysis of the provisions, this legislation will not have a material impact on our consolidated financial statements. The earnings represented by non-cash operating assets, such as fixed assets and inventory, will continue to be permanently reinvested outside the United States. Provisions of the U.S. Tax Cuts and Jobs Act (the Tax Act), such as the one-time tax on indefinitely reinvested earnings and the global intangible low-taxed income (GILTI) tax for years beginning in 2018, eliminate any additional U.S. taxation resulting from repatriation of earnings of non-U.S. subsidiaries to the United States. Consequently, no U.S. tax provision has been made for the future remittance of these earnings. However, withholding or distribution taxes in certain non-U.S. jurisdictions will be incurred upon repatriation of available cash to the United States. A provision has been made for deferred taxes on these undistributed earnings to the extent that repatriation of the available cash to the United States is expected to result in a tax liability. As of December 31, 2022, we have no basis differences that would result in material unrecognized deferred tax liabilities. We have made an allowable policy election to account for the effects of GILTI as a component of income tax expense in the period in which the tax is incurred. The primary components of deferred tax assets and liabilities are as follows: December 31, 2022 2021 Deferred tax assets: Capitalized R&D $ 380 $ — Deferred loss and tax credit carryforwards 201 207 Accrued expenses 182 209 Stock compensation 132 110 Inventories and related reserves 88 74 Retirement costs for defined benefit and retiree health care 43 — Other 36 40 Total deferred tax assets, before valuation allowance 1,062 640 Valuation allowance (189) (188) Total deferred tax assets, after valuation allowance 873 452 Deferred tax liabilities: Property, plant and equipment (410) (197) International earnings (35) (38) Retirement costs for defined benefit and retiree health care — (15) Acquisition-related intangibles and fair-value adjustments (13) (12) Other (8) (14) Total deferred tax liabilities (466) (276) Net deferred tax asset $ 407 $ 176 The deferred tax assets and liabilities based on tax jurisdictions are presented on our Consolidated Balance Sheets as follows: December 31, 2022 2021 Deferred tax assets $ 473 $ 263 Deferred tax liabilities (66) (87) Net deferred tax asset $ 407 $ 176 We make an ongoing assessment regarding the realization of U.S. and non-U.S. deferred tax assets. This assessment is based on our evaluation of relevant criteria, including the existence of deferred tax liabilities that can be used to absorb deferred tax assets, taxable income in prior carryback years and expectations for future taxable income. Valuation allowances increased $1 million in 2022, increased $9 million in 2021 and decreased $1 million in 2020. These changes had no impact to net income in 2022, 2021 or 2020. We have no material tax loss carryforwards as of December 31, 2022. Cash payments made for income taxes, net of refunds, were $1.48 billion, $1.20 billion and $720 million in 2022, 2021 and 2020, respectively. Uncertain tax positions We operate in a number of tax jurisdictions, and our income tax returns are subject to examination by tax authorities in those jurisdictions who may challenge any item on these tax returns. Because the matters challenged by authorities are typically complex, their ultimate outcome is uncertain. Before any benefit can be recorded in our financial statements, we must determine that it is “more likely than not” that a tax position will be sustained by the appropriate tax authorities. We recognize accrued interest related to uncertain tax positions and penalties as components of OI&E. The changes in the total amounts of uncertain tax positions are as follows: 2022 2021 2020 Balance, January 1 $ 69 $ 89 $ 303 Additions based on tax positions related to the current year 3 2 3 Additions for tax positions of prior years 10 7 35 Reductions for tax positions of prior years — (6) (249) Settlements with tax authorities — (23) — Expiration of the statute of limitations for assessing taxes — — (3) Balance, December 31 $ 82 $ 69 $ 89 Interest income (expense) recognized in the year ended December 31 $ (1) $ (5) $ 39 Interest payable as of December 31 $ 3 $ 13 $ 8 The liability for uncertain tax positions is a component of other long-term liabilities on our Consolidated Balance Sheets. All of the $82 million and $69 million liabilities for uncertain tax positions as of December 31, 2022 and 2021, respectively, are comprised of positions that, if recognized, would lower the effective tax rate. If these liabilities are ultimately realized, no existing deferred tax assets in 2022 or 2021 would also be realized. Reductions for tax positions of prior years in 2020 include a $249 million tax benefit for the effective settlement of a depreciation-related uncertain tax position. Accrued interest of $46 million related to this uncertain tax position was reversed and included in OI&E. As of December 31, 2022, the statute of limitations remains open for U.S. federal tax returns for 2017 and following years. Certain tax treaty procedures for relief from double taxation remain pending for U.S. federal tax returns for the years 2015 through 2021. In non-U.S. jurisdictions, the years open to audit represent the years still open under the statute of limitations. With respect to major jurisdictions outside the United States, our subsidiaries are no longer subject to income tax audits for years before 2012. |
Financial Instruments and Risk
Financial Instruments and Risk Concentration | 12 Months Ended |
Dec. 31, 2022 | |
Risks and Uncertainties [Abstract] | |
Financial instruments and risk concentration | Financial instruments and risk concentration Financial instruments We hold derivative financial instruments such as forward foreign currency exchange contracts, the fair value of which was not material as of December 31, 2022. Our forward foreign currency exchange contracts outstanding as of December 31, 2022, had a notional value of $387 million to hedge our non-U.S. dollar net balance sheet exposures, including $118 million to sell Japanese yen, $78 million to sell British pounds and $49 million to buy Chinese yuan. Our investments in cash equivalents, short-term investments and certain long-term investments, as well as our deferred compensation liabilities, are carried at fair value. Our postretirement plan assets are carried at fair value or net asset value per share. The carrying values for other current financial assets and liabilities, such as accounts receivable and accounts payable, approximate fair value due to the short maturity of such instruments. As of December 31, 2022, the carrying value of long-term debt, including the current portion, was $8.74 billion, and the estimated fair value was $7.86 billion. The estimated fair value is measured using broker-dealer quotes, which are Level 2 inputs. See Note 6 for a description of fair value and the definition of Level 2 inputs. Risk concentration We are subject to counterparty risks from financial institutions, customers and issuers of debt securities. Financial instruments that could subject us to concentrations of credit risk are primarily cash deposits, cash equivalents, short-term investments and accounts receivable. To manage our credit risk exposure, we place cash investments in investment-grade debt securities and limit the amount of credit exposure to any one issuer. We also limit counterparties on cash deposits and financial derivative contracts to financial institutions with investment-grade ratings. Concentrations of credit risk with respect to accounts receivable are limited due to our large number of customers and their dispersion across different industries and geographic areas. We maintain allowances for expected returns, disputes, adjustments, incentives and credit losses. These allowances are deducted from accounts receivable on our Consolidated Balance Sheets. Accounts receivable allowances changed to reflect amounts charged (credited) to operating results by $5 million, ($3) million and $3 million in 2022, 2021 and 2020, respectively. |
Valuation of Debt and Equity In
Valuation of Debt and Equity Investments and Certain Liabilities | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Valuation of debt and equity investments and certain liabilities | Valuation of debt and equity investments and certain liabilities Investments measured at fair value Money market funds, debt investments and mutual funds are stated at fair value, which is generally based on market prices or broker quotes. We classify all debt investments as available-for-sale. See Fair-value considerations. Unrealized gains and losses are recorded as an increase or decrease, net of taxes, in AOCI on our Consolidated Balance Sheets, and any credit losses are recorded as an allowance for credit losses with an offset recognized in OI&E in our Consolidated Statements of Income. Our mutual funds hold a variety of debt and equity investments intended to generate returns that offset changes in certain deferred compensation liabilities. We record changes in the fair value of these mutual funds and the related deferred compensation liabilities in SG&A. Other investments Our other investments include equity-method investments and non-marketable investments, which are not measured at fair value. These investments consist of interests in venture capital funds and other non-marketable securities. Gains and losses from equity-method investments are recognized in OI&E based on our ownership share of the investee’s financial results. Non-marketable securities are measured at cost with adjustments for observable changes in price or impairments. Gains and losses on non-marketable investments are recognized in OI&E. Details of our investments are as follows: December 31, 2022 December 31, 2021 Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash and Cash Equivalents Short-Term Investments Long-Term Investments Measured at fair value: Money market funds $ 1,238 $ — $ — $ 1,824 $ — $ — Corporate obligations 276 1,535 — 1,060 1,070 — U.S. government and agency securities 680 4,234 — 642 3,388 — Non-U.S. government and agency securities 149 248 — 300 650 — Mutual funds — — 11 — — 16 Total 2,343 6,017 11 3,826 5,108 16 Other measurement basis: Equity-method investments — — 18 — — 42 Non-marketable investments — — 5 — — 4 Cash on hand 707 — — 805 — — Total $ 3,050 $ 6,017 $ 34 $ 4,631 $ 5,108 $ 62 As of December 31, 2022 and 2021, unrealized gains and losses associated with our debt investments were not material. We did not recognize any credit losses related to debt investments in 2022, 2021 or 2020. The following table presents the aggregate maturities of our debt investments as of December 31, 2022: Fair Value One year or less $ 7,049 One to two years 73 In 2022, 2021 and 2020, the proceeds from sales, redemptions and maturities of short-term debt investments were $13.66 billion, $8.48 billion and $5.29 billion, respectively. Gross realized gains and losses from these sales were not material. In 2020, we entered into total return swaps to economically hedge the variability of certain deferred compensation obligations to employees. As a result, in 2020, we received proceeds of $253 million from the sale of investments in mutual funds that were previously being utilized to offset this exposure. Fair-value considerations We measure and report certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three-level hierarchy described below indicates the extent and level of judgment used to estimate fair-value measurements. • Level 1 – Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities as of the reporting date. • Level 2 – Uses inputs other than Level 1 that are either directly or indirectly observable as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data. We utilize a third-party data service to provide Level 2 valuations. We verify these valuations for reasonableness relative to unadjusted quotes obtained from brokers or dealers based on observable prices for similar assets in active markets. • Level 3 – Uses inputs that are unobservable, supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models that utilize management estimates of market participant assumptions. As of December 31, 2022 and 2021, we had no Level 3 assets or liabilities. The following are our assets and liabilities that were accounted for at fair value on a recurring basis. These tables do not include cash on hand, assets held by our postretirement plans, or assets and liabilities that are measured at historical cost or any basis other than fair value. December 31, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Assets: Money market funds $ 1,238 $ — $ 1,238 $ 1,824 $ — $ 1,824 Corporate obligations — 1,811 1,811 — 2,130 2,130 U.S. government and agency securities 4,914 — 4,914 3,629 401 4,030 Non-U.S. government and agency securities — 397 397 — 950 950 Mutual funds 11 — 11 16 — 16 Total assets $ 6,163 $ 2,208 $ 8,371 $ 5,469 $ 3,481 $ 8,950 Liabilities: Deferred compensation $ 326 $ — $ 326 $ 395 $ — $ 395 Total liabilities $ 326 $ — $ 326 $ 395 $ — $ 395 |
Postretirement Benefit Plans
Postretirement Benefit Plans | 12 Months Ended |
Dec. 31, 2022 | |
Retirement Benefits [Abstract] | |
Postretirement benefit plans | Postretirement benefit plans Plan descriptions We have various employee retirement plans, including defined contribution, defined benefit and retiree health care benefit plans. For qualifying employees, we offer deferred compensation arrangements. U.S. retirement plans Our principal retirement plans in the United States are a defined contribution plan, an enhanced defined contribution plan and qualified and non-qualified defined benefit pension plans. The defined benefit plans were closed to new participants in 1997, and then current participants were allowed to make a one-time election to continue accruing a benefit in the plans or to cease accruing a benefit and instead to participate in the enhanced defined contribution plan. Both defined contribution plans offer an employer-matching savings option that allows employees to make pretax and post-tax contributions to various investment choices. Employees who elected to continue accruing a benefit in the qualified defined benefit pension plans may also participate in the defined contribution plan, where employer-matching contributions are provided for up to 2% of the employee’s annual eligible earnings. Employees who elected not to continue accruing a benefit in the defined benefit pension plans and employees hired after November 1997 and through December 31, 2003, may participate in the enhanced defined contribution plan. This plan provides for a fixed employer contribution of 2% of the employee’s annual eligible earnings, plus an employer-matching contribution of up to 4% of the employee’s annual eligible earnings. Employees hired after December 31, 2003, do not receive the fixed employer contribution of 2% of the employee’s annual eligible earnings. As of December 31, 2022 and 2021, as a result of employees’ elections, TI’s U.S. defined contribution plans held shares of TI common stock totaling 6 million shares in both periods valued at $940 million and $1.16 billion, respectively. Dividends paid on these shares in 2022 and 2021 were $28 million and $27 million, respectively. Effective April 1, 2016, the TI common stock fund was frozen to new contributions or transfers into the fund. Our aggregate expense for the U.S. defined contribution plans was $70 million in 2022, $63 million in 2021 and $61 million in 2020. The defined benefit pension plans include employees still accruing benefits, as well as employees and participants who no longer accrue service-related benefits, but instead, may participate in the enhanced defined contribution plan. Benefits under the qualified defined benefit pension plan are determined using a formula based on years of service and the highest five U.S. retiree health care benefit plan U.S. employees who meet eligibility requirements are offered medical coverage during retirement. We make a contribution toward the cost of those retiree medical benefits for certain retirees and their dependents. The contribution rates are based upon various factors, the most important of which are an employee’s date of hire, date of retirement, years of service and eligibility for Medicare benefits. The balance of the cost is borne by the plan’s participants. Employees hired after January 1, 2001, are responsible for the full cost of their medical benefits during retirement. Non-U.S. retirement plans We provide retirement coverage for non-U.S. employees, as required by local laws or to the extent we deem appropriate, through a number of defined benefit and defined contribution plans. Retirement benefits are generally based on an employee’s years of service and compensation. Funding requirements are determined on an individual country and plan basis and are subject to local country practices and market circumstances. As of December 31, 2022 and 2021, as a result of employees’ elections, TI’s non-U.S. defined contribution plans held TI common stock valued at $33 million and $38 million, respectively. Dividends paid on these shares of TI common stock in 2022 and 2021 were not material. Effects on our Consolidated Statements of Income and Balance Sheets Expenses related to defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2020 2022 2021 2020 2022 2021 2020 Service cost $ 15 $ 21 $ 18 $ 3 $ 3 $ 3 $ 25 $ 36 $ 34 Interest cost 29 30 31 11 10 13 33 37 38 Expected return on plan assets (27) (31) (36) (12) (9) (12) (66) (81) (78) Amortization of prior service cost (credit) — — — (2) (2) (2) 1 1 1 Recognized net actuarial loss 3 15 7 — — — 1 7 14 Net periodic benefit costs 20 35 20 — 2 2 (6) — 9 Settlement losses 64 13 16 — — — 10 2 1 Total, including other postretirement losses $ 84 $ 48 $ 36 $ — $ 2 $ 2 $ 4 $ 2 $ 10 All defined benefit and retiree health care benefit plan expense components other than service cost are recognized in OI&E For the U.S. qualified pension and retiree health care plans, the expected return on plan assets component of net periodic benefit cost is based upon a market-related value of assets. In accordance with U.S. GAAP, the market-related value of assets is the fair value adjusted by a smoothing technique whereby certain gains and losses are phased in over a period of three years. Changes in the benefit obligations and plan assets for defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Change in plan benefit obligation Benefit obligation at beginning of year: $ 895 $ 1,097 $ 360 $ 389 $ 2,574 $ 2,868 Service cost 15 21 3 3 25 36 Interest cost 29 30 11 10 33 37 Participant contributions — — 15 14 5 9 Benefits paid (12) (12) (41) (38) (86) (101) Settlements (309) (162) — — (91) (12) Curtailments — — — — (4) — Actuarial loss (gain) (97) (79) (74) (18) (547) (111) Effects of exchange rate changes — — — — (242) (152) Benefit obligation at end of year $ 521 $ 895 $ 274 $ 360 $ 1,667 $ 2,574 Change in plan assets Fair value of plan assets at beginning of year: $ 934 $ 1,061 $ 385 $ 389 $ 2,813 $ 3,008 Actual return on plan assets (205) 37 (80) 19 (557) 75 Employer contributions (qualified plans) — — 1 1 9 7 Employer contributions (non-qualified plans) 13 10 — — — — Participant contributions — — 15 14 5 9 Benefits paid (12) (12) (41) (38) (86) (101) Settlements (309) (162) — — (91) (12) Effects of exchange rate changes — — — — (271) (173) Fair value of plan assets at end of year $ 421 $ 934 $ 280 $ 385 $ 1,822 $ 2,813 Funded status at end of year $ (100) $ 39 $ 6 $ 25 $ 155 $ 239 Changes in actuarial gains and losses in the projected benefit obligations are generally driven by discount rate movement. Amounts recognized on our Consolidated Balance Sheets as of December 31, are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Total 2022 Overfunded retirement plans $ — $ 8 $ 180 $ 188 Accrued expenses and other liabilities & other long-term liabilities (3) — (6) (9) Underfunded retirement plans (97) (2) (19) (118) Funded status at end of 2022 $ (100) $ 6 $ 155 $ 61 2021 Overfunded retirement plans $ 73 $ 28 $ 291 $ 392 Accrued expenses and other liabilities & other long-term liabilities (5) — (5) (10) Underfunded retirement plans (29) (3) (47) (79) Funded status at end of 2021 $ 39 $ 25 $ 239 $ 303 Contributions to the plans meet or exceed all minimum funding requirements. We expect to contribute about $10 million to our retirement benefit plans in 2023. Accumulated benefit obligations, which are generally less than the projected benefit obligations as they exclude the impact of future salary increases, were $489 million and $820 million as of December 31, 2022 and 2021, respectively, for the U.S. defined benefit plans, and $1.60 billion and $2.47 billion as of December 31, 2022 and 2021, respectively, for the non-U.S. defined benefit plans. The change in AOCI is as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Total Net Actuarial Loss Net Actuarial Loss Prior Service Cost Net Actuarial Loss Prior Service Cost Net Actuarial Loss Prior Service Cost AOCI balance, net of taxes, December 31, 2021 $ 36 $ (30) $ (1) $ 149 $ 1 $ 155 $ — Changes in AOCI by category: Adjustments 137 18 — 48 — 203 — Recognized within net income (67) — 2 (11) (1) (78) 1 Tax effect (16) (3) (1) (12) 1 (31) — Total change to AOCI 54 15 1 25 — 94 1 AOCI balance, net of taxes, December 31, 2022 $ 90 $ (15) $ — $ 174 $ 1 $ 249 $ 1 Information on plan assets We report and measure the plan assets of our defined benefit pension and other postretirement plans at fair value. The tables below set forth the fair value of our plan assets using the same three-level hierarchy of fair-value inputs described in Note 6. December 31, 2022 Level 1 Level 2 Other (a) Total Assets of U.S. defined benefit plan: Fixed income securities and cash equivalents $ — $ — $ 272 $ 272 Equity securities — — 149 149 Total $ — $ — $ 421 $ 421 Assets of U.S. retiree health care plan: Fixed income securities and cash equivalents $ 7 $ — $ 175 $ 182 Equity securities — — 98 98 Total $ 7 $ — $ 273 $ 280 Assets of non-U.S. defined benefit plans: Fixed income securities and cash equivalents $ 40 $ 60 $ 1,282 $ 1,382 Equity securities 52 1 387 440 Total $ 92 $ 61 $ 1,669 $ 1,822 (a) Consists of bond index and equity index funds, measured at net asset value per share, as well as cash equivalents. December 31, 2021 Level 1 Level 2 Other (a) Total Assets of U.S. defined benefit plan: Fixed income securities and cash equivalents $ — $ — $ 655 $ 655 Equity securities — — 279 279 Total $ — $ — $ 934 $ 934 Assets of U.S. retiree health care plan: Fixed income securities and cash equivalents $ 10 $ — $ 238 $ 248 Equity securities — — 137 137 Total $ 10 $ — $ 375 $ 385 Assets of non-U.S. defined benefit plans: Fixed income securities and cash equivalents $ 71 $ 104 $ 2,045 $ 2,220 Equity securities 49 2 542 593 Total $ 120 $ 106 $ 2,587 $ 2,813 (a) Consists of bond index and equity index funds, measured at net asset value per share, as well as cash equivalents. The investments in our major benefit plans largely consist of low-cost, broad-market index funds to mitigate risks of concentration within market sectors. Our investment policy is designed to better match the interest rate sensitivity of the plan assets and liabilities. The appropriate mix of equity and bond investments is determined primarily through the use of detailed asset-liability modeling studies that look to balance the impact of changes in the discount rate against the need to provide asset growth to cover future service cost. Most of our plans around the world have a greater proportion of fixed income securities with return characteristics that are more closely aligned with changes in the liabilities caused by discount rate volatility. Assumptions and investment policies U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Weighted average assumptions used to determine benefit obligations: Discount rate 5.67% 2.74% 5.68% 3.05% 3.45% 1.57% Long-term pay progression 3.75% 3.70% n/a n/a 3.03% 3.15% Weighted average assumptions used to determine net periodic benefit cost: Discount rate 3.82% 2.95% 3.05% 2.74% 1.57% 1.31% Long-term rate of return on plan assets 3.80% 3.50% 3.40% 3.10% 2.73% 2.82% Long-term pay progression 3.70% 3.70% n/a n/a 3.15% 3.15% We utilize a variety of methods to select an appropriate discount rate depending on the depth of the corporate bond market in the country in which the benefit plan operates. In the United States, we use a settlement approach whereby a portfolio of bonds is selected from the universe of actively traded high-quality U.S. corporate bonds. The selected portfolio is designed to simulate a portfolio that would provide cash flows sufficient to pay the plan’s expected benefit payments when due. The resulting discount rate reflects the rate of return of the selected portfolio of bonds. For our non-U.S. locations with a sufficient number of actively traded high-quality bonds, an analysis is performed in which the projected cash flows from the defined benefit plans are discounted against a yield curve constructed with an appropriate universe of high-quality corporate bonds available in each country. In this manner, a present value is developed. The discount rate selected is the single equivalent rate that produces the same present value. For countries that lack a sufficient corporate bond market, a government bond index is used to establish the discount rate. Assumptions for the expected long-term rate of return on plan assets are based on future expectations for returns for each asset class and the effect of periodic target asset allocation rebalancing. We adjust the results for the payment of reasonable expenses of the plan from plan assets. We believe our assumptions are appropriate based on the investment mix and long-term nature of the plans’ investments. Assumptions used for the non-U.S. defined benefit plans reflect the different economic environments within the various countries. The target allocation ranges for the plans that hold a substantial majority of the defined benefit assets are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Fixed income securities and cash equivalents 65% – 80% 65% – 80% 60% – 100% Equity securities 20% – 35% 20% – 35% 0% – 40% We rebalance the plans’ investments when they are outside the target allocation ranges. Weighted average asset allocations as of December 31 are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Fixed income securities and cash equivalents 65% 70% 65% 64% 76% 79% Equity securities 35% 30% 35% 36% 24% 21% None of the plan assets related to the defined benefit pension plans and retiree health care benefit plan are directly invested in TI common stock. The following assumed future benefit payments to plan participants in the next 10 years are used to measure our benefit obligations. Almost all of the payments, which may vary significantly from these assumptions, will be made from plan assets and not from company assets. 2023 2024 2025 2026 2027 2028 – 2032 U.S. Defined Benefit $ 77 $ 75 $ 65 $ 63 $ 60 $ 227 U.S. Retiree Health Care 28 27 26 25 24 106 Non-U.S. Defined Benefit 84 87 89 91 92 487 Assumed health care cost trend rates for the U.S. retiree health care benefit plan as of December 31 are as follows: 2022 2021 Assumed health care cost trend rate for next year 7.00% 6.50% Ultimate trend rate 5.00% 5.00% Year in which ultimate trend rate is reached 2031 2028 Deferred compensation plans We have deferred compensation plans that allow U.S. employees whose base salary and management responsibility exceed a certain level to defer receipt of a portion of their cash compensation. Payments under these plans are made based on the participant’s distribution election and plan balance. Participants can earn a return on their deferred compensation based on notional investments in the same investment funds that are offered in our defined contribution plans. As of December 31, 2022, our liability to participants of the deferred compensation plans was $326 million and is recorded in other long-term liabilities on our Consolidated Balance Sheets. This amount reflects the accumulated participant deferrals and earnings thereon as of that date. We utilize total return swaps and investments in mutual funds that serve as economic hedges of our exposure to changes in the fair value of these liabilities. We record changes in the fair value of the liability and the related total return swaps and mutual funds in SG&A, as discussed in Note 6. As of December 31, 2022, we held $11 million in mutual funds related to these plans that are recorded in long-term investments on our Consolidated Balance Sheets. |
Debt and Lines of Credit
Debt and Lines of Credit | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
Debt and lines of credit | Debt and lines of credit Short-term borrowings We maintain a line of credit to provide additional liquidity through bank loans and, if necessary, to support commercial paper borrowings. As of December 31, 2022, the aforementioned line of credit was a variable-rate, revolving credit facility from a consortium of investment-grade banks that allows us to borrow up to $1 billion until March 2023. The interest rate on borrowings under this credit facility, if drawn, is indexed to the applicable Term Secured Overnight Financing Rate (Term SOFR). As of December 31, 2022, our credit facility was undrawn, and we had no commercial paper outstanding. Long-term debt In April 2022, we retired $500 million of maturing debt. In August 2022, we issued two series of senior unsecured notes for an aggregate principal amount of $700 million, consisting of $400 million of 3.65% notes due in 2032 and $300 million of 4.10% notes due in 2052. We incurred $3 million of issuance and other related costs. The proceeds of the offering were $695 million, net of the original issuance discounts, which will be used for general corporate purposes. In November 2022, we issued two series of senior unsecured notes for an aggregate principal amount of $800 million, consisting of $300 million of 4.70% notes due in 2024 and $500 million of 4.60% notes due in 2028. We incurred $3 million of issuance and other related costs. The proceeds of the offering were $799 million, net of the original issuance discounts, which will be used for general corporate purposes. In February 2021, we retired $550 million of maturing debt. In September 2021, we issued three series of senior unsecured notes for an aggregate principal amount of $1.5 billion, consisting of $500 million of 1.125% notes due in 2026, $500 million of 1.90% notes due in 2031 and $500 million of 2.70% notes due in 2051. We incurred $10 million of issuance costs. The proceeds of the offering were $1.5 billion, net of the original issuance discounts, which will be used for general corporate purposes. In March 2020, we issued a principal amount of $750 million of fixed-rate, long-term debt due in 2025. We incurred $4 million of issuance costs. The proceeds of the offering were $749 million, net of the original issuance discount, and were used for general corporate purposes and the repayment of maturing debt. In April 2020, we retired $500 million of maturing debt. In May 2020, we issued a principal amount of $750 million of fixed-rate, long-term debt due in 2030. We incurred $5 million of issuance costs. The proceeds of the offering were $749 million, net of the original issuance discount, and were used for general corporate purposes. Long-term debt outstanding is as follows: December 31, 2022 2021 Notes due 2022 at 1.85% $ — $ 500 Notes due 2023 at 2.25% 500 500 Notes due 2024 at 2.625% 300 300 Notes due 2024 at 4.70% 300 — Notes due 2025 at 1.375% 750 750 Notes due 2026 at 1.125% 500 500 Notes due 2027 at 2.90% 500 500 Notes due 2028 at 4.60% 500 — Notes due 2029 at 2.25% 750 750 Notes due 2030 at 1.75% 750 750 Notes due 2031 at 1.90% 500 500 Notes due 2032 at 3.65% 400 — Notes due 2039 at 3.875% 750 750 Notes due 2048 at 4.15% 1,500 1,500 Notes due 2051 at 2.70% 500 500 Notes due 2052 at 4.10% 300 — Total debt 8,800 7,800 Net unamortized discounts, premiums and issuance costs (65) (59) Total debt, including net unamortized discounts, premiums and issuance costs 8,735 7,741 Current portion of long-term debt (500) (500) Long-term debt $ 8,235 $ 7,241 Interest and debt expense was $214 million, $184 million and $190 million in 2022, 2021 and 2020, respectively. This was net of the amortized discounts, premiums and issuance and other related costs. Cash payments for interest on long-term debt were $198 million, $181 million and $182 million in 2022, 2021 and 2020, respectively. Capitalized interest was not material. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2022 | |
Leases [Abstract] | |
Leases | Leases We conduct certain operations in leased facilities and also lease a portion of our data processing and other equipment. In addition, certain long-term supply agreements to purchase industrial gases are accounted for as operating leases. Lease agreements frequently include renewal provisions and require us to pay real estate taxes, insurance and maintenance costs. Our leases are included as a component of the following balance sheet lines: December 31, 2022 2021 Other long-term assets $ 431 $ 465 Accrued expenses and other liabilities $ 75 $ 82 Other long-term liabilities 344 383 Details of our operating leases are as follows: For Years Ended 2022 2021 2020 Lease cost related to lease liabilities $ 67 $ 69 $ 70 Variable lease cost 46 56 36 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease cost $ 61 $ 61 $ 59 Lease assets obtained in exchange for new lease liabilities $ 37 $ 210 $ 59 As of December 31, 2022, we had committed to make the following minimum payments under our non-cancellable operating leases: 2023 2024 2025 2026 2027 Thereafter Total Lease payments $ 81 $ 65 $ 54 $ 48 $ 41 $ 185 $ 474 Imputed lease interest (55) Total lease liabilities $ 419 The weighted-average remaining lease term was 8.8 years and 9.2 years as of December 31, 2022 and 2021, respectively. The weighted-average discount rate was 2.71% and 2.51% as of December 31, 2022 and 2021, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | Commitments and contingencies Purchase commitments Our purchase commitments include payments for software licenses and contractual arrangements with suppliers when there is a fixed, non-cancellable payment schedule or when minimum payments are due with a reduced delivery schedule. As of December 31, 2022, we had committed to make the following minimum payments under our purchase commitments: 2023 2024 2025 2026 2027 Thereafter Total Purchase commitments $ 502 $ 529 $ 260 $ 236 $ 242 $ 337 $ 2,106 Indemnification guarantees We routinely sell products with an intellectual property indemnification included in the terms of sale. Historically, we have had only minimal, infrequent losses associated with these indemnities. Consequently, we cannot reasonably estimate any future liabilities that may result. Warranty costs/product liabilities Our stated warranties for semiconductor products obligate us to repair, replace or credit the purchase price of a covered product back to the buyer. Product claim consideration may exceed the price of our products. Historically, we have experienced a low rate of payments on product claims. Although we cannot predict the likelihood or amount of any future claims, we do not believe they will have a material adverse effect on our consolidated financial statements. We accrue for known product-related claims if a loss is probable and can be reasonably estimated. During the periods presented, there have been no material accruals or payments regarding product warranty or product liability. General We are subject to various legal and administrative proceedings. Although it is not possible to predict the outcome of these matters, we believe that the results of these proceedings will not have a material adverse effect on our consolidated financial statements. |
Supplemental financial informat
Supplemental financial information | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block Supplement [Abstract] | |
Supplemental financial information | Supplemental financial information Restructuring charges/other Restructuring charges/other are included in Other for segment reporting purposes and are comprised of the following components: For Years Ended December 31, 2022 2021 2020 Restructuring charges (a) $ — $ — $ 25 Integration charges (b) 257 104 — Gains on sales of assets (c) — (50) (1) Restructuring charges/other $ 257 $ 54 $ 24 (a) Includes severance and benefits, changes in estimates and other exit costs. (b) Includes costs related to our purchase of the Lehi, Utah, manufacturing facility, as well as preproduction costs before December 2022. (c) Includes a $50 million gain from the sale of property in October 2021. Other income (expense), net (OI&E) For Years Ended December 31, 2022 2021 2020 Other income (a) $ 168 $ 145 $ 327 Other expense (b) (62) (2) (14) Total $ 106 $ 143 $ 313 (a) Other income includes interest, royalty and lease income, as well as investment gains and losses and reversals of tax interest accruals. (b) Other expense includes a portion of pension and other retiree benefit costs, currency gains and losses and miscellaneous items. Property, plant and equipment at cost Depreciable Lives (Years) December 31, 2022 2021 Land n/a $ 132 $ 132 Buildings and improvements 5 – 40 4,154 3,490 Machinery and equipment 2 – 10 5,664 4,236 Total $ 9,950 $ 7,858 Goodwill Goodwill by segment as of December 31, 2022 and 2021, is as follows: Goodwill Analog $ 4,158 Embedded Processing 172 Other 32 Total $ 4,362 We perform our annual goodwill impairment test in the fourth quarter and determine whether the fair value of each of our reporting units is in excess of its carrying value. In 2022, we elected to perform a qualitative analysis to assess impairment of goodwill rather than to perform the quantitative goodwill impairment test. The key qualitative factors considered in the assessment included changes in the industry and competitive environment, market capitalization and overall financial performance. Based on this qualitative analysis, we determined that it was more likely than not that the fair value of each reporting unit exceeded its carrying value. In 2022, 2021 and 2020, we determined no impairment was indicated. Accrued expenses and other liabilities December 31, 2022 2021 Accrued construction retainage $ 149 $ 82 Other 497 520 Total $ 646 $ 602 Other long-term liabilities December 31, 2022 2021 Operating lease liabilities $ 344 $ 383 Deferred compensation plans 326 395 Long-term portion of transition tax on indefinitely reinvested earnings 302 403 Other 254 186 Total $ 1,226 $ 1,367 Accumulated other comprehensive income (loss), net of taxes (AOCI) December 31, 2022 2021 Postretirement benefit plans: Net actuarial loss $ (249) $ (155) Prior service cost (1) — Unrealized losses on available-for-sale investments (3) — Cash flow hedge derivative instruments (1) (2) Total $ (254) $ (157) Details on amounts reclassified out of accumulated other comprehensive income (loss), net of taxes, to net income Our Consolidated Statements of Comprehensive Income include items that have been recognized within net income in 2022, 2021 and 2020. The table below details where these transactions are recorded in our Consolidated Statements of Income. For Years Ended December 31, Impact to Related Statement of Income Lines 2022 2021 2020 Net actuarial losses of defined benefit plans: Recognized net actuarial loss and settlement losses (a) $ 78 $ 37 $ 38 Decrease to OI&E Tax effect (17) (8) (9) Decrease to provision for income taxes Recognized within net income, net of taxes $ 61 $ 29 $ 29 Decrease to net income Prior service cost of defined benefit plans: Amortization of prior service cost (a) $ (1) $ (1) $ (1) Increase to OI&E Tax effect — — — Increase to provision for income taxes Recognized within net income, net of taxes $ (1) $ (1) $ (1) Increase to net income (a) Detailed in Note 7 |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies and Practices (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of presentation | Basis of presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The basis of these financial statements is comparable for all periods presented herein. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. All dollar and share amounts in the financial statements and tables in these notes, except per-share amounts, are presented in millions unless otherwise indicated. We have reclassified certain amounts in the prior periods’ financial statements to conform to the 2022 presentation. The preparation of financial statements requires the use of estimates from which final results may vary. |
Revenue recognition | Revenue recognition We generate revenue primarily from the sale of semiconductor products, either directly to a customer or to a distributor, and recognize revenue when control is transferred. Control is considered transferred when title and risk of loss pass, when the customer becomes obligated to pay and, where required, when the customer has accepted the products. This transfer generally occurs at a point in time upon shipment or delivery to the customer or distributor, depending upon the terms of the sales order. Payment for sales to customers and distributors is generally due on our standard commercial terms. For sales to distributors, payment is not contingent upon resale of the products. Revenue from sales of our products that are subject to inventory consignment agreements is recognized at a point in time, when the customer or distributor pulls product from consignment inventory that we store at designated locations. Delivery and transfer of control occur at that point, when title and risk of loss transfers and the customer or distributor becomes obligated to pay for the products pulled from inventory. Until the products are pulled for use or sale by the customer or distributor, we retain control over the products’ disposition, including the right to pull back or relocate the products. The revenue recognized is adjusted based on allowances, which are prepared on a portfolio basis using a most likely amount methodology based on analysis of historical data and contractual terms. These allowances, which are not material, generally include adjustments for pricing arrangements, product returns , incentives and credit losses. We recognize shipping fees received from customers, if any, in revenue. We include the related shipping and handling costs in cost of revenue. The majority of our customers pay these fees directly to third parties. |
Advertising costs | Advertising costsWe expense advertising and other promotional costs as incurred. |
Income taxes | Income taxes We account for income taxes using an asset and liability approach. We record the amount of taxes payable or refundable for the current year and the deferred tax assets and liabilities for future tax consequences related to events that have been recognized in the financial statements or tax returns. We record a valuation allowance when it is more likely than not that some or all of the deferred tax assets will not be realized. |
Other assessed taxes | Other assessed taxes Some transactions require us to collect taxes such as sales, value-added and excise taxes from our customers. These transactions are presented in our Consolidated Statements of Income on a net (excluded from revenue) basis. |
Leases | Leases We determine if an arrangement is a lease at inception. Leases are included in other long-term assets, accrued expenses and other liabilities, and other long-term liabilities on our Consolidated Balance Sheets. Lease assets represent our right to use underlying assets for the lease term, and lease liabilities represent our obligations to make lease payments over the lease term. On the commencement date, leases are evaluated for classification, and assets and liabilities are recognized based on the present value of lease payments over the lease term. We use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. Operating lease expense is generally recognized on a straight-line basis over the lease term. Our lease values include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. We have agreements with lease and non-lease components, which are accounted for as a single lease component. Leases with an initial lease term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. |
Earnings per share (EPS) | Earnings per share (EPS) We use the two-class method for calculating EPS because the restricted stock units (RSUs) we grant are participating securities containing non-forfeitable rights to receive dividend equivalents. Under the two-class method, a portion of net income is allocated to RSUs and excluded from the calculation of income allocated to common stock. |
Investments | Investments We present investments on our Consolidated Balance Sheets as cash equivalents, short-term investments or other long-term assets. See Note 6 for additional information. • Cash equivalents and short-term investments – The primary objectives of our cash equivalent and short-term investment activities are to preserve capital and maintain liquidity while generating appropriate returns. We consider investments in available-for-sale debt securities with maturities of 90 days or less from the date of our investment to be cash equivalents. We consider investments in available-for-sale debt securities with maturities beyond 90 days from the date of our investment as being available for use in current operations and include them in short-term investments. • Other long-term assets – Long-term investments, which are included within other long-term assets on our Consolidated Balance Sheets, consist of mutual funds, venture capital funds and non-marketable securities. Investments measured at fair value Money market funds, debt investments and mutual funds are stated at fair value, which is generally based on market prices or broker quotes. We classify all debt investments as available-for-sale. See Fair-value considerations. Unrealized gains and losses are recorded as an increase or decrease, net of taxes, in AOCI on our Consolidated Balance Sheets, and any credit losses are recorded as an allowance for credit losses with an offset recognized in OI&E in our Consolidated Statements of Income. Our mutual funds hold a variety of debt and equity investments intended to generate returns that offset changes in certain deferred compensation liabilities. We record changes in the fair value of these mutual funds and the related deferred compensation liabilities in SG&A. Other investments Our other investments include equity-method investments and non-marketable investments, which are not measured at fair value. These investments consist of interests in venture capital funds and other non-marketable securities. Gains and losses from equity-method investments are recognized in OI&E based on our ownership share of the investee’s financial results. Non-marketable securities are measured at cost with adjustments for observable changes in price or impairments. Gains and losses on non-marketable investments are recognized in OI&E. |
Inventories | Inventories Inventories are stated at the lower of cost or estimated net realizable value. Cost is generally computed on a currently adjusted standard cost basis, which approximates cost on a first-in, first-out basis. Standard cost is based on the normal utilization of installed factory capacity. Cost associated with underutilization of capacity is expensed as incurred. Inventory held at consignment locations is included in our finished goods inventory. We review inventory quarterly for salability and obsolescence. A statistical allowance is provided for inventory considered unlikely to be sold. The statistical allowance is based on an analysis of historical disposal activity, historical customer shipments, as well as estimated future sales. A specific allowance for each material type will be carried if there is a significant event not captured by the statistical allowance. We write off inventory in the period in which disposal occurs. |
Government incentives | Government incentives Incentives provided by government entities are recognized when we have reasonable assurance that we will comply with the conditions of the incentive, if any, and the incentive will be received. Incentives related to the acquisition or construction of fixed assets are recognized as a reduction in the carrying amounts of the related assets and reduce depreciation expense over the useful lives of the assets. Incentives for specific operating activities are offset against the related expense in the period the expense is incurred. |
Property, plant and equipment; acquisition-related intangibles and other capitalized costs | Property, plant and equipment; acquisition-related intangibles; and other capitalized costs Property, plant and equipment are stated at cost and depreciated over their estimated useful lives using the straight-line method. Our cost basis includes certain assets acquired in business combinations that were initially recorded at fair value as of the date of acquisition. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining lease term or the estimated useful lives of the improvements. We amortize acquisition-related intangibles on a straight-line basis over the estimated economic life of the assets. Capitalized software licenses are generally amortized on a straight-line basis over the term of the license. Fully depreciated or amortized assets are written off against accumulated depreciation or amortization. |
Impairments of long-lived assets | Impairments of long-lived assets We regularly review whether facts or circumstances exist that indicate the carrying values of property, plant and equipment or other long-lived assets, including intangible assets, are impaired. We assess the recoverability of assets by comparing the projected undiscounted net cash flows associated with those assets to their respective carrying amounts. Any impairment charge is based on the excess of the carrying amount over the fair value of those assets. Fair value is determined by available market valuations, if applicable, or by discounted cash flows. |
Goodwill | Goodwill Goodwill is reviewed for impairment annually in the fourth quarter or more frequently if certain impairment indicators arise. We perform a qualitative assessment to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying value, including goodwill. If we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying value, or if we elect not to use the qualitative assessment, then we perform the quantitative goodwill impairment test. See Note 11 for additional information. |
Foreign currency | Foreign currency The functional currency for our non-U.S. subsidiaries is the U.S. dollar. Accounts recorded in currencies other than the U.S. dollar are remeasured into the functional currency. Current assets (except inventories), deferred taxes, other long-term assets, current liabilities and long-term liabilities are remeasured at exchange rates in effect at the end of each reporting period. Property, plant and equipment with associated depreciation and inventories are valued at historical exchange rates. Revenue and expense accounts other than depreciation for each month are calculated at the appropriate daily rate of exchange. Currency exchange gains and losses from remeasurement are credited or charged to OI&E. |
Derivatives and hedging | Derivatives and hedging We use derivative financial instruments to manage exposure to foreign exchange risk. These instruments are primarily forward foreign currency exchange contracts, which are used as economic hedges to reduce the earnings impact that exchange rate fluctuations may have on our non-U.S. dollar net balance sheet exposures. Gains and losses from changes in the fair value of these forward foreign currency exchange contracts are credited or charged to OI&E. We do not apply hedge accounting to our foreign currency derivative instruments. We are exposed to variability in compensation charges related to certain deferred compensation obligations to employees. We use total return swaps to economically hedge this exposure and offset the related compensation expense, recognizing changes in the value of the swaps and the related deferred compensation liabilities in SG&A. In connection with the issuance of long-term debt, we may use financial derivatives such as treasury-rate lock agreements that are recognized in AOCI and amortized over the life of the related debt. The results of these derivative transactions were not material. We do not use derivatives for speculative or trading purposes. |
Stock compensation | We recognize compensation expense for non-qualified stock options and RSUs on a straight-line basis over the minimum service period required for vesting of the award, adjusting for estimated forfeitures based on historical activity. Awards issued to employees who are retirement eligible or nearing retirement eligibility are expensed on an accelerated basis. Options issued under our ESPP are expensed over a three-month period. We use market-based measures of implied volatility to determine expected volatility on all options granted. We determine expected lives of options based on the historical option exercise experience of our option holders using a rolling 10-year average. Expected dividend yields are based on the annualized approved quarterly dividend rate and the current market price of our common stock at the time of grant. No assumption for a future dividend rate change is included unless there is an approved plan to change the dividend in the near term. |
Fair values considerations | Fair-value considerations We measure and report certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three-level hierarchy described below indicates the extent and level of judgment used to estimate fair-value measurements. • Level 1 – Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities as of the reporting date. • Level 2 – Uses inputs other than Level 1 that are either directly or indirectly observable as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data. We utilize a third-party data service to provide Level 2 valuations. We verify these valuations for reasonableness relative to unadjusted quotes obtained from brokers or dealers based on observable prices for similar assets in active markets. • Level 3 – Uses inputs that are unobservable, supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models that utilize management estimates of market participant assumptions. As of December 31, 2022 and 2021, we had no Level 3 assets or liabilities. |
Indemnification guarantees and warranty costs/product liabilities | Indemnification guarantees We routinely sell products with an intellectual property indemnification included in the terms of sale. Historically, we have had only minimal, infrequent losses associated with these indemnities. Consequently, we cannot reasonably estimate any future liabilities that may result. Warranty costs/product liabilities Our stated warranties for semiconductor products obligate us to repair, replace or credit the purchase price of a covered product back to the buyer. Product claim consideration may exceed the price of our products. Historically, we have experienced a low rate of payments on product claims. Although we cannot predict the likelihood or amount of any future claims, we do not believe they will have a material adverse effect on our consolidated financial statements. We accrue for known product-related claims if a loss is probable and can be reasonably estimated. During the periods presented, there have been no material accruals or payments regarding product warranty or product liability. |
Description of Business, Incl_2
Description of Business, Including Segment and Geographic Area Information (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
Schedule of Revenue and Operating Profit, by Segment | Segment information For Years Ended December 31, 2022 2021 2020 Revenue: Analog $ 15,359 $ 14,050 $ 10,886 Embedded Processing 3,261 3,049 2,570 Other 1,408 1,245 1,005 Total revenue $ 20,028 $ 18,344 $ 14,461 Operating profit: Analog $ 8,359 $ 7,393 $ 4,912 Embedded Processing 1,253 1,174 743 Other 528 393 239 Total operating profit $ 10,140 $ 8,960 $ 5,894 |
Schedule of Revenue, by Geographic Area | Geographic area information The following geographic information is based on product shipment destination, which does not reflect end demand by geography. For Years Ended December 31, 2022 2021 2020 Revenue: United States $ 2,267 11 % $ 1,906 10 % $ 1,547 11 % China (a) 9,844 49 9,998 55 7,881 54 Rest of Asia 2,633 13 2,187 12 1,660 11 Europe, Middle East and Africa 3,520 18 2,802 15 2,249 16 Japan 1,172 6 959 5 734 5 Rest of world 592 3 492 3 390 3 Total revenue $ 20,028 100 % $ 18,344 100 % $ 14,461 100 % (a) Revenue from products shipped into China includes shipments to customers that manufacture in China and then export end products to their customers around the world, as well as distributors that transship inventory through China to service other countries. The following additional geographic information includes our estimate for revenue based on the location of our end customers’ headquarters, providing a better representation of the geographic profile for where critical decisions are made. For Years Ended December 31, 2022 2021 2020 Revenue: United States $ 6,609 33 % $ 6,237 34 % $ 5,205 36 % China 4,807 24 4,586 25 3,326 23 Rest of Asia 2,003 10 2,018 11 1,591 11 Europe, Middle East and Africa (a) 4,807 24 3,852 21 3,037 21 Japan 1,602 8 1,468 8 1,157 8 Rest of world 200 1 183 1 145 1 Total revenue $ 20,028 100 % $ 18,344 100 % $ 14,461 100 % (a) Revenue from end customers headquartered in Germany was 11%, 9% and 9% of total revenue in 2022, 2021 and 2020, respectively. |
Schedule Property, Plant and Equipment by Geographic Area | Property, plant and equipment by geographic area, based on physical location: December 31, 2022 2021 Property, plant and equipment: United States $ 5,134 $ 3,648 China 648 570 Rest of Asia 896 722 Europe, Middle East and Africa 44 47 Japan 121 139 Rest of world 33 15 Total property, plant and equipment $ 6,876 $ 5,141 |
Basis of Presentation and Sig_3
Basis of Presentation and Significant Accounting Policies and Practices (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Earnings per Share, Basic and Diluted | Computation and reconciliation of earnings per common share are as follows: For Years Ended December 31, 2022 2021 2020 Net Income Shares EPS Net Income Shares EPS Net Income Shares EPS Basic EPS: Net income $ 8,749 $ 7,769 $ 5,595 Income allocated to RSUs (40) (33) (27) Income allocated to common stock $ 8,709 916 $ 9.51 $ 7,736 923 $ 8.38 $ 5,568 921 $ 6.05 Dilutive effect of stock compensation plans 10 13 12 Diluted EPS: Net income $ 8,749 $ 7,769 $ 5,595 Income allocated to RSUs (39) (33) (27) Income allocated to common stock $ 8,710 926 $ 9.41 $ 7,736 936 $ 8.26 $ 5,568 933 $ 5.97 |
Stock Compensation (Tables)
Stock Compensation (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Stock Compensation Expense Allocation Within the Consolidated Statements of Income | Total stock compensation expense recognized is as follows: For Years Ended December 31, 2022 2021 2020 COR $ 34 $ 21 $ 21 R&D 90 67 68 SG&A 165 134 135 Restructuring charges/other — 8 — Total $ 289 $ 230 $ 224 |
Schedule of Weighted Average Assumptions Used to Estimate the Fair Values for Non-qualified Stock Options | We estimate the fair values for non-qualified stock options using the Black-Scholes-Merton option-pricing model with the following weighted average assumptions: For Years Ended December 31, 2022 2021 2020 Weighted average grant date fair value, per share $ 39.94 $ 40.78 $ 25.55 Weighted average assumptions used: Expected volatility 29 % 32 % 26 % Expected lives (in years) 6.4 6.7 6.8 Risk-free interest rates 1.83 % 0.72 % 1.53 % Expected dividend yields 2.64 % 2.41 % 2.76 % |
Schedule of Stock Option and RSU Transactions Under Long-term Incentive and Director Compensation Plans | Stock option and RSU transactions under our long-term incentive and director compensation plans are as follows: Stock Options RSUs Shares Weighted Average Exercise Price per Share Shares Weighted Average Grant Date Fair Value per Share Outstanding grants, December 31, 2021 25 $ 91.58 4 $ 124.80 Granted 4 $ 174.60 2 $ 174.39 Stock options exercised/RSUs vested (4) $ 67.64 (1) $ 112.87 Outstanding grants, December 31, 2022 (a) 25 $ 105.75 5 $ 147.30 (a) Forfeited and expired shares were not material. For Years Ended December 31, 2022 2021 2020 Weighted average grant date fair value per share for RSUs $ 174.39 $ 176.08 $ 130.59 Total grant date fair value of shares vested for RSUs $ 121 $ 115 $ 110 Aggregate intrinsic value of options exercised $ 336 $ 611 $ 681 |
Schedule of Shares Outstanding Under Stock Option Plans, by Exercise Price Range | Summarized information about stock options outstanding as of December 31, 2022, is as follows: Stock Options Outstanding Exercise Price Range Number Outstanding (Shares) Weighted Average Remaining Contractual Life (Years) $32.48 to $193.58 25 5.3 |
Schedule of Stock Options That are Vested and Expected to Vest, Outstanding and Exercisable | Options Fully Vested and Expected to Vest (a) Options Exercisable Options outstanding (shares) 25 17 Weighted average remaining contractual life (in years) 5.3 4.0 Weighted average exercise price per share $ 105.25 $ 81.56 Intrinsic value (billions) $ 1.54 $ 1.42 (a) Includes effects of expected forfeitures. Excluding the effects of expected forfeitures, the aggregate intrinsic value of stock options outstanding was $1.54 billion. |
Schedule of Changes in Treasury Stock | The following table reflects the changes in our treasury shares: For Years Ended December 31, 2022 2021 2020 Balance, January 1 817 821 809 Repurchases 22 3 23 Shares issued (4) (7) (11) Balance, December 31 835 817 821 |
Schedule of Cash Proceeds Received from Share-based Payment Awards | The effects on cash flows are as follows: For Years Ended December 31, 2022 2021 2020 Proceeds from common stock transactions (a) $ 241 $ 377 $ 470 Tax benefit realized from stock compensation 110 175 195 (a) Net of taxes paid for employee shares withheld of $50 million, $53 million and $53 million in 2022, 2021 and 2020, respectively. |
Income taxes (Tables)
Income taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income before income taxes | Income before income taxes is comprised of the following components: For Years Ended December 31, 2022 2021 2020 U.S. $ 9,122 $ 7,998 $ 5,210 Non-U.S. 910 921 807 Total $ 10,032 $ 8,919 $ 6,017 |
Provision for income taxes | Provision for income taxes is comprised of the following components: For Years Ended December 31, 2022 2021 2020 Current Deferred Total Current Deferred Total Current Deferred Total U.S. federal $ 1,235 $ (223) $ 1,012 $ 948 $ (23) $ 925 $ 357 $ (122) $ 235 Non-U.S. 212 32 244 169 38 207 192 (15) 177 U.S. state 27 — 27 18 — 18 10 — 10 Total $ 1,474 $ (191) $ 1,283 $ 1,135 $ 15 $ 1,150 $ 559 $ (137) $ 422 |
Principal reconciliation items from U.S. statutory income tax rate to the effective tax rate | Principal reconciling items from the U.S. statutory income tax rate to the effective tax rate (provision for income taxes as a percentage of income before income taxes) are as follows: For Years Ended December 31, 2022 2021 2020 U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Foreign derived intangible income (7.0) (6.1) (6.1) R&D tax credit (0.9) (0.9) (1.3) Stock compensation (0.7) (1.5) (2.5) Changes in uncertain tax positions 0.1 (0.2) (4.0) Other 0.3 0.6 (0.1) Effective tax rate 12.8 % 12.9 % 7.0 % |
Primary components of deferred tax assets and liabilities | The primary components of deferred tax assets and liabilities are as follows: December 31, 2022 2021 Deferred tax assets: Capitalized R&D $ 380 $ — Deferred loss and tax credit carryforwards 201 207 Accrued expenses 182 209 Stock compensation 132 110 Inventories and related reserves 88 74 Retirement costs for defined benefit and retiree health care 43 — Other 36 40 Total deferred tax assets, before valuation allowance 1,062 640 Valuation allowance (189) (188) Total deferred tax assets, after valuation allowance 873 452 Deferred tax liabilities: Property, plant and equipment (410) (197) International earnings (35) (38) Retirement costs for defined benefit and retiree health care — (15) Acquisition-related intangibles and fair-value adjustments (13) (12) Other (8) (14) Total deferred tax liabilities (466) (276) Net deferred tax asset $ 407 $ 176 The deferred tax assets and liabilities based on tax jurisdictions are presented on our Consolidated Balance Sheets as follows: December 31, 2022 2021 Deferred tax assets $ 473 $ 263 Deferred tax liabilities (66) (87) Net deferred tax asset $ 407 $ 176 |
Summary of uncertain tax positions | The changes in the total amounts of uncertain tax positions are as follows: 2022 2021 2020 Balance, January 1 $ 69 $ 89 $ 303 Additions based on tax positions related to the current year 3 2 3 Additions for tax positions of prior years 10 7 35 Reductions for tax positions of prior years — (6) (249) Settlements with tax authorities — (23) — Expiration of the statute of limitations for assessing taxes — — (3) Balance, December 31 $ 82 $ 69 $ 89 Interest income (expense) recognized in the year ended December 31 $ (1) $ (5) $ 39 Interest payable as of December 31 $ 3 $ 13 $ 8 |
Valuation of Debt and Equity _2
Valuation of Debt and Equity Investments and Certain Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Investments | Details of our investments are as follows: December 31, 2022 December 31, 2021 Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash and Cash Equivalents Short-Term Investments Long-Term Investments Measured at fair value: Money market funds $ 1,238 $ — $ — $ 1,824 $ — $ — Corporate obligations 276 1,535 — 1,060 1,070 — U.S. government and agency securities 680 4,234 — 642 3,388 — Non-U.S. government and agency securities 149 248 — 300 650 — Mutual funds — — 11 — — 16 Total 2,343 6,017 11 3,826 5,108 16 Other measurement basis: Equity-method investments — — 18 — — 42 Non-marketable investments — — 5 — — 4 Cash on hand 707 — — 805 — — Total $ 3,050 $ 6,017 $ 34 $ 4,631 $ 5,108 $ 62 |
Aggregate Maturities of Available-for-sale Debt Investments | The following table presents the aggregate maturities of our debt investments as of December 31, 2022: Fair Value One year or less $ 7,049 One to two years 73 |
Assets and Liabilities Accounted for at Fair Value | The following are our assets and liabilities that were accounted for at fair value on a recurring basis. These tables do not include cash on hand, assets held by our postretirement plans, or assets and liabilities that are measured at historical cost or any basis other than fair value. December 31, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Assets: Money market funds $ 1,238 $ — $ 1,238 $ 1,824 $ — $ 1,824 Corporate obligations — 1,811 1,811 — 2,130 2,130 U.S. government and agency securities 4,914 — 4,914 3,629 401 4,030 Non-U.S. government and agency securities — 397 397 — 950 950 Mutual funds 11 — 11 16 — 16 Total assets $ 6,163 $ 2,208 $ 8,371 $ 5,469 $ 3,481 $ 8,950 Liabilities: Deferred compensation $ 326 $ — $ 326 $ 395 $ — $ 395 Total liabilities $ 326 $ — $ 326 $ 395 $ — $ 395 |
Postretirement Benefit Plans (T
Postretirement Benefit Plans (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Retirement Benefits [Abstract] | |
Expense Related to Defined Benefit and Retiree Health Care Benefit Plans | Expenses related to defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2020 2022 2021 2020 2022 2021 2020 Service cost $ 15 $ 21 $ 18 $ 3 $ 3 $ 3 $ 25 $ 36 $ 34 Interest cost 29 30 31 11 10 13 33 37 38 Expected return on plan assets (27) (31) (36) (12) (9) (12) (66) (81) (78) Amortization of prior service cost (credit) — — — (2) (2) (2) 1 1 1 Recognized net actuarial loss 3 15 7 — — — 1 7 14 Net periodic benefit costs 20 35 20 — 2 2 (6) — 9 Settlement losses 64 13 16 — — — 10 2 1 Total, including other postretirement losses $ 84 $ 48 $ 36 $ — $ 2 $ 2 $ 4 $ 2 $ 10 |
Schedule of Changes in the Benefit Obligations and Plan Assets for the Defined Benefit and Retiree Health Care Benefit Plans | Changes in the benefit obligations and plan assets for defined benefit and retiree health care benefit plans are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Change in plan benefit obligation Benefit obligation at beginning of year: $ 895 $ 1,097 $ 360 $ 389 $ 2,574 $ 2,868 Service cost 15 21 3 3 25 36 Interest cost 29 30 11 10 33 37 Participant contributions — — 15 14 5 9 Benefits paid (12) (12) (41) (38) (86) (101) Settlements (309) (162) — — (91) (12) Curtailments — — — — (4) — Actuarial loss (gain) (97) (79) (74) (18) (547) (111) Effects of exchange rate changes — — — — (242) (152) Benefit obligation at end of year $ 521 $ 895 $ 274 $ 360 $ 1,667 $ 2,574 Change in plan assets Fair value of plan assets at beginning of year: $ 934 $ 1,061 $ 385 $ 389 $ 2,813 $ 3,008 Actual return on plan assets (205) 37 (80) 19 (557) 75 Employer contributions (qualified plans) — — 1 1 9 7 Employer contributions (non-qualified plans) 13 10 — — — — Participant contributions — — 15 14 5 9 Benefits paid (12) (12) (41) (38) (86) (101) Settlements (309) (162) — — (91) (12) Effects of exchange rate changes — — — — (271) (173) Fair value of plan assets at end of year $ 421 $ 934 $ 280 $ 385 $ 1,822 $ 2,813 Funded status at end of year $ (100) $ 39 $ 6 $ 25 $ 155 $ 239 |
Schedule of Amounts Recognized in our Balance Sheet | Amounts recognized on our Consolidated Balance Sheets as of December 31, are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Total 2022 Overfunded retirement plans $ — $ 8 $ 180 $ 188 Accrued expenses and other liabilities & other long-term liabilities (3) — (6) (9) Underfunded retirement plans (97) (2) (19) (118) Funded status at end of 2022 $ (100) $ 6 $ 155 $ 61 2021 Overfunded retirement plans $ 73 $ 28 $ 291 $ 392 Accrued expenses and other liabilities & other long-term liabilities (5) — (5) (10) Underfunded retirement plans (29) (3) (47) (79) Funded status at end of 2021 $ 39 $ 25 $ 239 $ 303 |
Schedule of Change in AOCI | The change in AOCI is as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Total Net Actuarial Loss Net Actuarial Loss Prior Service Cost Net Actuarial Loss Prior Service Cost Net Actuarial Loss Prior Service Cost AOCI balance, net of taxes, December 31, 2021 $ 36 $ (30) $ (1) $ 149 $ 1 $ 155 $ — Changes in AOCI by category: Adjustments 137 18 — 48 — 203 — Recognized within net income (67) — 2 (11) (1) (78) 1 Tax effect (16) (3) (1) (12) 1 (31) — Total change to AOCI 54 15 1 25 — 94 1 AOCI balance, net of taxes, December 31, 2022 $ 90 $ (15) $ — $ 174 $ 1 $ 249 $ 1 |
Schedule of Allocation of Plan Assets | The tables below set forth the fair value of our plan assets using the same three-level hierarchy of fair-value inputs described in Note 6. December 31, 2022 Level 1 Level 2 Other (a) Total Assets of U.S. defined benefit plan: Fixed income securities and cash equivalents $ — $ — $ 272 $ 272 Equity securities — — 149 149 Total $ — $ — $ 421 $ 421 Assets of U.S. retiree health care plan: Fixed income securities and cash equivalents $ 7 $ — $ 175 $ 182 Equity securities — — 98 98 Total $ 7 $ — $ 273 $ 280 Assets of non-U.S. defined benefit plans: Fixed income securities and cash equivalents $ 40 $ 60 $ 1,282 $ 1,382 Equity securities 52 1 387 440 Total $ 92 $ 61 $ 1,669 $ 1,822 (a) Consists of bond index and equity index funds, measured at net asset value per share, as well as cash equivalents. December 31, 2021 Level 1 Level 2 Other (a) Total Assets of U.S. defined benefit plan: Fixed income securities and cash equivalents $ — $ — $ 655 $ 655 Equity securities — — 279 279 Total $ — $ — $ 934 $ 934 Assets of U.S. retiree health care plan: Fixed income securities and cash equivalents $ 10 $ — $ 238 $ 248 Equity securities — — 137 137 Total $ 10 $ — $ 375 $ 385 Assets of non-U.S. defined benefit plans: Fixed income securities and cash equivalents $ 71 $ 104 $ 2,045 $ 2,220 Equity securities 49 2 542 593 Total $ 120 $ 106 $ 2,587 $ 2,813 (a) Consists of bond index and equity index funds, measured at net asset value per share, as well as cash equivalents. The target allocation ranges for the plans that hold a substantial majority of the defined benefit assets are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit Fixed income securities and cash equivalents 65% – 80% 65% – 80% 60% – 100% Equity securities 20% – 35% 20% – 35% 0% – 40% Weighted average asset allocations as of December 31 are as follows: U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Fixed income securities and cash equivalents 65% 70% 65% 64% 76% 79% Equity securities 35% 30% 35% 36% 24% 21% |
Schedule of Assumptions Used | Assumptions and investment policies U.S. Defined Benefit U.S. Retiree Health Care Non-U.S. Defined Benefit 2022 2021 2022 2021 2022 2021 Weighted average assumptions used to determine benefit obligations: Discount rate 5.67% 2.74% 5.68% 3.05% 3.45% 1.57% Long-term pay progression 3.75% 3.70% n/a n/a 3.03% 3.15% Weighted average assumptions used to determine net periodic benefit cost: Discount rate 3.82% 2.95% 3.05% 2.74% 1.57% 1.31% Long-term rate of return on plan assets 3.80% 3.50% 3.40% 3.10% 2.73% 2.82% Long-term pay progression 3.70% 3.70% n/a n/a 3.15% 3.15% |
Schedule of Assumed Future Benefit Payments | The following assumed future benefit payments to plan participants in the next 10 years are used to measure our benefit obligations. Almost all of the payments, which may vary significantly from these assumptions, will be made from plan assets and not from company assets. 2023 2024 2025 2026 2027 2028 – 2032 U.S. Defined Benefit $ 77 $ 75 $ 65 $ 63 $ 60 $ 227 U.S. Retiree Health Care 28 27 26 25 24 106 Non-U.S. Defined Benefit 84 87 89 91 92 487 |
Schedule of Assumed Health Care Cost Trend Rates for U.S Retiree Health Care Benefit Plan | Assumed health care cost trend rates for the U.S. retiree health care benefit plan as of December 31 are as follows: 2022 2021 Assumed health care cost trend rate for next year 7.00% 6.50% Ultimate trend rate 5.00% 5.00% Year in which ultimate trend rate is reached 2031 2028 |
Debt and Lines of Credit (Table
Debt and Lines of Credit (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt Instruments | Long-term debt outstanding is as follows: December 31, 2022 2021 Notes due 2022 at 1.85% $ — $ 500 Notes due 2023 at 2.25% 500 500 Notes due 2024 at 2.625% 300 300 Notes due 2024 at 4.70% 300 — Notes due 2025 at 1.375% 750 750 Notes due 2026 at 1.125% 500 500 Notes due 2027 at 2.90% 500 500 Notes due 2028 at 4.60% 500 — Notes due 2029 at 2.25% 750 750 Notes due 2030 at 1.75% 750 750 Notes due 2031 at 1.90% 500 500 Notes due 2032 at 3.65% 400 — Notes due 2039 at 3.875% 750 750 Notes due 2048 at 4.15% 1,500 1,500 Notes due 2051 at 2.70% 500 500 Notes due 2052 at 4.10% 300 — Total debt 8,800 7,800 Net unamortized discounts, premiums and issuance costs (65) (59) Total debt, including net unamortized discounts, premiums and issuance costs 8,735 7,741 Current portion of long-term debt (500) (500) Long-term debt $ 8,235 $ 7,241 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Leases [Abstract] | |
Balance sheet components of leases | Our leases are included as a component of the following balance sheet lines: December 31, 2022 2021 Other long-term assets $ 431 $ 465 Accrued expenses and other liabilities $ 75 $ 82 Other long-term liabilities 344 383 |
Schedule of Operating Leases | Details of our operating leases are as follows: For Years Ended 2022 2021 2020 Lease cost related to lease liabilities $ 67 $ 69 $ 70 Variable lease cost 46 56 36 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease cost $ 61 $ 61 $ 59 Lease assets obtained in exchange for new lease liabilities $ 37 $ 210 $ 59 |
Maturities of operating leases | As of December 31, 2022, we had committed to make the following minimum payments under our non-cancellable operating leases: 2023 2024 2025 2026 2027 Thereafter Total Lease payments $ 81 $ 65 $ 54 $ 48 $ 41 $ 185 $ 474 Imputed lease interest (55) Total lease liabilities $ 419 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Minimum Payments Under Purchase Commitments | As of December 31, 2022, we had committed to make the following minimum payments under our purchase commitments: 2023 2024 2025 2026 2027 Thereafter Total Purchase commitments $ 502 $ 529 $ 260 $ 236 $ 242 $ 337 $ 2,106 |
Supplemental financial inform_2
Supplemental financial information (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block Supplement [Abstract] | |
Restructuring charges and other | Restructuring charges/other are included in Other for segment reporting purposes and are comprised of the following components: For Years Ended December 31, 2022 2021 2020 Restructuring charges (a) $ — $ — $ 25 Integration charges (b) 257 104 — Gains on sales of assets (c) — (50) (1) Restructuring charges/other $ 257 $ 54 $ 24 (a) Includes severance and benefits, changes in estimates and other exit costs. (b) Includes costs related to our purchase of the Lehi, Utah, manufacturing facility, as well as preproduction costs before December 2022. (c) Includes a $50 million gain from the sale of property in October 2021. |
Other income (expense), net (OI&E) | Other income (expense), net (OI&E) For Years Ended December 31, 2022 2021 2020 Other income (a) $ 168 $ 145 $ 327 Other expense (b) (62) (2) (14) Total $ 106 $ 143 $ 313 (a) Other income includes interest, royalty and lease income, as well as investment gains and losses and reversals of tax interest accruals. (b) Other expense includes a portion of pension and other retiree benefit costs, currency gains and losses and miscellaneous items. |
Property, plant and equipment at cost | Property, plant and equipment at cost Depreciable Lives (Years) December 31, 2022 2021 Land n/a $ 132 $ 132 Buildings and improvements 5 – 40 4,154 3,490 Machinery and equipment 2 – 10 5,664 4,236 Total $ 9,950 $ 7,858 |
Schedule of goodwill | Goodwill by segment as of December 31, 2022 and 2021, is as follows: Goodwill Analog $ 4,158 Embedded Processing 172 Other 32 Total $ 4,362 |
Accrued expenses and other liabilities | Accrued expenses and other liabilities December 31, 2022 2021 Accrued construction retainage $ 149 $ 82 Other 497 520 Total $ 646 $ 602 |
Other long-term liabilities | Other long-term liabilities December 31, 2022 2021 Operating lease liabilities $ 344 $ 383 Deferred compensation plans 326 395 Long-term portion of transition tax on indefinitely reinvested earnings 302 403 Other 254 186 Total $ 1,226 $ 1,367 |
Accumulated other comprehensive income (loss), net of taxes (AOCI) | Accumulated other comprehensive income (loss), net of taxes (AOCI) December 31, 2022 2021 Postretirement benefit plans: Net actuarial loss $ (249) $ (155) Prior service cost (1) — Unrealized losses on available-for-sale investments (3) — Cash flow hedge derivative instruments (1) (2) Total $ (254) $ (157) |
Amounts reclassified out of accumulated other comprehensive income (loss), net of taxes, to net income | The table below details where these transactions are recorded in our Consolidated Statements of Income. For Years Ended December 31, Impact to Related Statement of Income Lines 2022 2021 2020 Net actuarial losses of defined benefit plans: Recognized net actuarial loss and settlement losses (a) $ 78 $ 37 $ 38 Decrease to OI&E Tax effect (17) (8) (9) Decrease to provision for income taxes Recognized within net income, net of taxes $ 61 $ 29 $ 29 Decrease to net income Prior service cost of defined benefit plans: Amortization of prior service cost (a) $ (1) $ (1) $ (1) Increase to OI&E Tax effect — — — Increase to provision for income taxes Recognized within net income, net of taxes $ (1) $ (1) $ (1) Increase to net income (a) Detailed in Note 7 |
Description of Business, Incl_3
Description of Business, Including Segment and Geographic Area Information - Additional Information (Details) - reportable_segment | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Segment Reporting [Abstract] | |||
Number of reportable segments | 2 | ||
Customer Number One | Revenue Benchmark | Customer Concentration Risk | |||
Major Customer [Line Items] | |||
Concentration risk | 8% | 9% | 10% |
Description of Business, Incl_4
Description of Business, Including Segment and Geographic Area Information - Schedule of Revenue and Operating Profit by Segment (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Segment Reporting Information [Line Items] | |||
Total revenue | $ 20,028 | $ 18,344 | $ 14,461 |
Total operating profit | 10,140 | 8,960 | 5,894 |
Analog | |||
Segment Reporting Information [Line Items] | |||
Total revenue | 15,359 | 14,050 | 10,886 |
Total operating profit | 8,359 | 7,393 | 4,912 |
Embedded Processing | |||
Segment Reporting Information [Line Items] | |||
Total revenue | 3,261 | 3,049 | 2,570 |
Total operating profit | 1,253 | 1,174 | 743 |
Other | |||
Segment Reporting Information [Line Items] | |||
Total revenue | 1,408 | 1,245 | 1,005 |
Total operating profit | $ 528 | $ 393 | $ 239 |
Description of Business, Incl_5
Description of Business, Including Segment and Geographic Area Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 20,028 | $ 18,344 | $ 14,461 | |
Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 20,028 | $ 18,344 | $ 14,461 | |
Concentration risk | 100% | 100% | 100% | |
Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 20,028 | $ 18,344 | $ 14,461 | |
Concentration risk | 100% | 100% | 100% | |
United States | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 2,267 | $ 1,906 | $ 1,547 | |
Concentration risk | 11% | 10% | 11% | |
United States | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 6,609 | $ 6,237 | $ 5,205 | |
Concentration risk | 33% | 34% | 36% | |
China | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | [1] | $ 9,844 | $ 9,998 | $ 7,881 |
Concentration risk | [1] | 49% | 55% | 54% |
China | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 4,807 | $ 4,586 | $ 3,326 | |
Concentration risk | 24% | 25% | 23% | |
Rest of Asia | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 2,633 | $ 2,187 | $ 1,660 | |
Concentration risk | 13% | 12% | 11% | |
Rest of Asia | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 2,003 | $ 2,018 | $ 1,591 | |
Concentration risk | 10% | 11% | 11% | |
Europe, Middle East and Africa | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 3,520 | $ 2,802 | $ 2,249 | |
Concentration risk | 18% | 15% | 16% | |
Europe, Middle East and Africa | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | [2] | $ 4,807 | $ 3,852 | $ 3,037 |
Concentration risk | [2] | 24% | 21% | 21% |
Japan | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 1,172 | $ 959 | $ 734 | |
Concentration risk | 6% | 5% | 5% | |
Japan | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 1,602 | $ 1,468 | $ 1,157 | |
Concentration risk | 8% | 8% | 8% | |
Rest of world | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Shipment Destination | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 592 | $ 492 | $ 390 | |
Concentration risk | 3% | 3% | 3% | |
Rest of world | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Total revenue | $ 200 | $ 183 | $ 145 | |
Concentration risk | 1% | 1% | 1% | |
Germany | Revenue from Contract with Customer, Product and Service Benchmark | Geographic Concentration Risk, Customers' Headquarters | ||||
Segment Reporting Information [Line Items] | ||||
Concentration risk | 11% | 9% | 9% | |
[1]Revenue from products shipped into China includes shipments to customers that manufacture in China and then export end products to their customers around the world, as well as distributors that transship inventory through China to service other countries.[2]Revenue from end customers headquartered in Germany was 11%, 9% and 9% of total revenue in 2022, 2021 and 2020, respectively. |
Description of Business, Incl_6
Description of Business, Including Segment and Geographic Area Information - Schedule of Property, Plant and Equipment by Geographic Area (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | $ 6,876 | $ 5,141 |
United States | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | 5,134 | 3,648 |
China | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | 648 | 570 |
Rest of Asia | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | 896 | 722 |
Europe, Middle East and Africa | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | 44 | 47 |
Japan | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | 121 | 139 |
Rest of world | ||
Segment Reporting Information [Line Items] | ||
Total property, plant and equipment | $ 33 | $ 15 |
Basis of Presentation and Sig_4
Basis of Presentation and Significant Accounting Policies and Practices - Additional Information (Details) - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Advertising expense | $ 27 | $ 27 | $ 28 |
Antidilutive securities excluded from computation of earnings per share, Amount (in shares) | 5 | 3 | 4 |
Maximum length to maturity of a security, from the investment date, where it is classified as cash and cash equivalent | 90 days | ||
Length to maturity from the investment date of a security where the length of time is too short to be classified as a short-term investment | 90 days | ||
Receivables in other long-term assets | $ 395 | ||
Government Assistance, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other long-term assets |
Basis of Presentation and Sig_5
Basis of Presentation and Significant Accounting Policies and Practices - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Basic EPS: | |||
Net income | $ 8,749 | $ 7,769 | $ 5,595 |
Income allocated to RSUs | (40) | (33) | (27) |
Income allocated to common stock for basic EPS | $ 8,709 | $ 7,736 | $ 5,568 |
Weighted average number of shares outstanding, basic (in shares) | 916 | 923 | 921 |
Basic earnings per common share (in dollars per share) | $ 9.51 | $ 8.38 | $ 6.05 |
Dilutive effect of stock compensation plans | 10 | 13 | 12 |
Diluted EPS: | |||
Net income | $ 8,749 | $ 7,769 | $ 5,595 |
Income allocated to RSUs | (39) | (33) | (27) |
Income allocated to common stock for diluted EPS | $ 8,710 | $ 7,736 | $ 5,568 |
Weighted average number of shares outstanding, diluted (in shares) | 926 | 936 | 933 |
Diluted earnings per common share (in dollars per share) | $ 9.41 | $ 8.26 | $ 5.97 |
Stock Compensation - Additional
Stock Compensation - Additional Information (Details) shares in Millions, $ in Millions | 12 Months Ended |
Dec. 31, 2022 USD ($) shares | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |
Number of shares remaining available for future issuance (in shares) | shares | 32 |
Future compensation not yet recognized in the Statements of Income | $ | $ 440 |
Weighted average recognition period | 1 year 10 months 24 days |
Remaining stock repurchase authorizations | $ | $ 21,480 |
Employee stock purchase plan | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |
Percent of the underlying common stock's market price participants pay for options (in hundredths) | 85% |
Number of shares remaining available for future issuance (in shares) | shares | 32 |
ESPP option term (in months) | 3 months |
Long-term incentive and director compensation plans | Employee Stock Option | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |
Term of the long term incentive stock options | 10 years |
Award vesting period (in years) | 4 years |
Long-term incentive and director compensation plans | Restricted Stock Units (RSUs) | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |
Award vesting period (in years) | 4 years |
Stock Compensation - Expense (D
Stock Compensation - Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock compensation | $ 289 | $ 230 | $ 224 |
COR | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock compensation | 34 | 21 | 21 |
R&D | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock compensation | 90 | 67 | 68 |
SG&A | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock compensation | 165 | 134 | 135 |
Restructuring charges/other | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock compensation | $ 0 | $ 8 | $ 0 |
Stock Compensation - Fair-value
Stock Compensation - Fair-value Methods and Assumptions (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-Based Payment Arrangement [Abstract] | |||
Weighted average grant date fair value, per share (in dollars per share) | $ 39.94 | $ 40.78 | $ 25.55 |
Expected volatility (in percent) | 29% | 32% | 26% |
Expected lives | 6 years 4 months 24 days | 6 years 8 months 12 days | 6 years 9 months 18 days |
Risk-free interest rates (in percent) | 1.83% | 0.72% | 1.53% |
Expected dividend yields (in percent) | 2.64% | 2.41% | 2.76% |
Stock Compensation - Stock Opti
Stock Compensation - Stock Options and RSUs Outstanding (Details) - Long-term incentive and director compensation plans - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Employee Stock Option | |||
Stock Options, Shares | |||
Options outstanding, Beginning balance (in shares) | 25 | ||
Granted (in shares) | 4 | ||
Exercised (in shares) | (4) | ||
Options outstanding, Ending balance (in shares) | 25 | 25 | |
Stock Options, Weighted Average Exercise Price per Share | |||
Weighted-average exercise price, Outstanding, Beginning of period (in dollars per share) | $ 91.58 | ||
Weighted-average exercise price, Granted (in dollars per share) | 174.60 | ||
Weighted-average exercise price, Exercised (in dollars per share) | 67.64 | ||
Weighted-average exercise price, Outstanding, End of period (in dollars per share) | $ 105.75 | $ 91.58 | |
Restricted Stock Units, Weighted Average Grant Date Fair Value per Share | |||
Aggregate intrinsic values of options exercised | $ 336 | $ 611 | $ 681 |
Restricted Stock Units (RSUs) | |||
Restricted Stock Units, Shares | |||
Awards outstanding other than options, Beginning balance (in shares) | 4 | ||
Granted (in shares) | 2 | ||
Vested (in shares) | (1) | ||
Awards outstanding other than options, Ending balance (in shares) | 5 | 4 | |
Restricted Stock Units, Weighted Average Grant Date Fair Value per Share | |||
Weighted-average grant date fair value, Beginning of period (in dollars per share) | $ 124.80 | ||
Weighted-average grant-date fair value, Granted (in dollars per share) | 174.39 | $ 176.08 | $ 130.59 |
Weighted-average grant date fair value, Vested (in dollars per share) | 112.87 | ||
Weighted-average grant date fair value, Ending of period (in dollars per share) | 147.30 | 124.80 | |
Weighted-average grant-date fair value, Granted (in dollars per share) | $ 174.39 | $ 176.08 | $ 130.59 |
Total fair values of shares vested from RSU lapses | $ 121 | $ 115 | $ 110 |
Stock Compensation - Exercise P
Stock Compensation - Exercise Price Range (Details) - Employee Stock Option - Long-term incentive and director compensation plans - $ / shares shares in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise Price Range, Minimum (in dollars per share) | $ 32.48 | |
Exercise Price Range, Maximum (in dollars per share) | $ 193.58 | |
Number Outstanding (Shares) | 25 | 25 |
Weighted Average Remaining Contractual Life (Years) | 5 years 3 months 18 days | |
Options Outstanding Weighted Average Exercise Price per Share (in dollars per share) | $ 105.75 | $ 91.58 |
Stock Compensation - Options Ve
Stock Compensation - Options Vested and Expected to Vest (Details) - Long-term incentive and director compensation plans - Employee Stock Option $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | |
Dec. 31, 2022 USD ($) $ / shares shares | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Options outstanding, vested and expected to vest (in shares) | shares | 25 | [1] |
Weighted average remaining contractual life, vested and expected to vest (in years) | 5 years 3 months 18 days | [1] |
Weighted average exercise price per share, vested and expected to vest (in dollars per share) | $ / shares | $ 105.25 | [1] |
Intrinsic value, vested and expected to vest (millions of dollars) | $ 1,540 | [1] |
Outstanding options exercisable (in shares) | shares | 17 | |
Weighted average remaining contractual life, options exercisable | 4 years | |
Weighted average exercise price per share, options exercisable (in dollars per share) | $ / shares | $ 81.56 | |
Intrinsic value, options exercisable (millions of dollars) | $ 1,420 | |
Aggregate intrinsic value of stock options outstanding, excluding the effects of expected forfeitures | $ 1,540 | |
[1]Includes effects of expected forfeitures. Excluding the effects of expected forfeitures, the aggregate intrinsic value of stock options outstanding was $1.54 billion. |
Stock Compensation - Effect on
Stock Compensation - Effect on Shares Outstanding and Treasury Shares (Details) - shares shares in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Change In Treasury Stock Roll Forward [Roll Forward] | ||||
Treasury stock (in shares) | 835 | 817 | 821 | 809 |
Repurchases (in shares) | 22 | 3 | 23 | |
Shares issued (in shares) | (4) | (7) | (11) |
Stock Compensation - Effects on
Stock Compensation - Effects on Cash Flows (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Share-Based Payment Arrangement [Abstract] | ||||
Proceeds from common stock transactions | [1] | $ 241 | $ 377 | $ 470 |
Tax benefit realized from stock compensation | 110 | 175 | 195 | |
Taxes paid for employee shares withheld | $ 50 | $ 53 | $ 53 | |
[1]Net of taxes paid for employee shares withheld of $50 million, $53 million and $53 million in 2022, 2021 and 2020, respectively. |
Income taxes - Income before in
Income taxes - Income before income taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
U.S. | $ 9,122 | $ 7,998 | $ 5,210 |
Non-U.S. | 910 | 921 | 807 |
Income before income taxes | $ 10,032 | $ 8,919 | $ 6,017 |
Income taxes - Provision for in
Income taxes - Provision for income taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
U.S. federal - Current | $ 1,235 | $ 948 | $ 357 |
Non-U.S. - Current | 212 | 169 | 192 |
U.S. state - Current | 27 | 18 | 10 |
Total current income tax expense (benefit) | 1,474 | 1,135 | 559 |
U.S. federal - Deferred | (223) | (23) | (122) |
Non-U.S. - Deferred | 32 | 38 | (15) |
U.S. state - Deferred | 0 | 0 | 0 |
Total deferred income tax expense (benefit) | (191) | 15 | (137) |
Total U.S. federal income taxes | 1,012 | 925 | 235 |
Total Non-U.S. income taxes | 244 | 207 | 177 |
Total U.S. state income taxes | 27 | 18 | 10 |
Provision for income taxes | $ 1,283 | $ 1,150 | $ 422 |
Income taxes - Reconciliation i
Income taxes - Reconciliation items from U.S. statutory income tax rate to the effective tax rate (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
U.S. statutory income tax rate | 21% | 21% | 21% |
Foreign derived intangible income | (7.00%) | (6.10%) | (6.10%) |
R&D tax credit | (0.90%) | (0.90%) | (1.30%) |
Stock compensation | (0.70%) | (1.50%) | (2.50%) |
Changes in uncertain tax positions | 0.10% | (0.20%) | (4.00%) |
Other | 0.30% | 0.60% | (0.10%) |
Effective tax rate | 12.80% | 12.90% | 7% |
Income taxes - Components of de
Income taxes - Components of deferred tax assets and liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred tax assets: | ||
Capitalized R&D | $ 380 | $ 0 |
Deferred loss and tax credit carryforwards | 201 | 207 |
Accrued expenses | 182 | 209 |
Stock compensation | 132 | 110 |
Inventories and related reserves | 88 | 74 |
Retirement costs for defined benefit and retiree health care | 43 | 0 |
Other | 36 | 40 |
Total deferred tax assets, before valuation allowance | 1,062 | 640 |
Valuation allowance | (189) | (188) |
Total deferred tax assets, after valuation allowance | 873 | 452 |
Deferred tax liabilities: | ||
Property, plant and equipment | (410) | (197) |
International earnings | (35) | (38) |
Retirement costs for defined benefit and retiree health care | 0 | (15) |
Acquisition-related intangibles and fair-value adjustments | (13) | (12) |
Other | (8) | (14) |
Total deferred tax liabilities | (466) | (276) |
Net deferred tax asset | $ 407 | $ 176 |
Income taxes - Deferred tax ass
Income taxes - Deferred tax assets and liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Income Tax Disclosure [Abstract] | ||
Deferred tax assets | $ 473 | $ 263 |
Deferred tax liabilities | (66) | (87) |
Net deferred tax asset | $ 407 | $ 176 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | ||||
Change in deferred tax asset valuation allowances | $ 1,000,000 | $ 9,000,000 | $ (1,000,000) | |
Net income impacted due to change in valuation allowances | 0 | 0 | 0 | |
Tax loss carryforward, U.S. and non-U.S. | 0 | |||
Cash payments for income taxes | 1,480,000,000 | 1,200,000,000 | 720,000,000 | |
Liabilities for uncertain tax positions | 82,000,000 | 69,000,000 | 89,000,000 | $ 303,000,000 |
Amount of tax benefit for tax settlements | $ 0 | $ (6,000,000) | (249,000,000) | |
Accrued interest related to uncertain tax position | $ 46,000,000 |
Income taxes - Uncertain tax po
Income taxes - Uncertain tax positions (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Balance, January 1 | $ 69 | $ 89 | $ 303 |
Additions based on tax positions related to the current year | 3 | 2 | 3 |
Additions for tax positions of prior years | 10 | 7 | 35 |
Reductions for tax positions of prior years | 0 | (6) | (249) |
Settlements with tax authorities | 0 | (23) | 0 |
Expiration of the statute of limitations for assessing taxes | 0 | 0 | (3) |
Balance, December 31 | 82 | 69 | 89 |
Interest income (expense) recognized in the year ended December 31 | (1) | (5) | 39 |
Interest payable as of December 31 | $ 3 | $ 13 | $ 8 |
Financial Instruments and Ris_2
Financial Instruments and Risk Concentration - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Carrying value of long term debt | $ 8,735 | $ 7,741 | |
Allowance for Credit Loss | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Accounts receivable allowances, amounts charged (credited) to operating results | 5 | $ (3) | $ 3 |
Level 2 | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Fair value of long term debt | 7,860 | ||
Foreign Exchange Forward | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Notional amount | 387 | ||
Foreign Exchange Forward | Japanese Yen | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Notional amount | 118 | ||
Foreign Exchange Forward | British Pounds | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Notional amount | 78 | ||
Foreign Exchange Forward | Yuan | |||
Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Notional amount | $ 49 |
Valuation of Debt and Equity _3
Valuation of Debt and Equity Investments and Certain Liabilities - Investments at Fair Value (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | $ 3,050 | $ 4,631 |
Short-term investments | 6,017 | 5,108 |
Long-term Investments | 34 | 62 |
Measured at fair value | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 2,343 | 3,826 |
Short-term investments | 6,017 | 5,108 |
Long-term Investments | 11 | 16 |
Measured at fair value | Available-for-sale debt securities | Money market funds | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 1,238 | 1,824 |
Short-term investments | 0 | 0 |
Long-term Investments | 0 | 0 |
Measured at fair value | Available-for-sale debt securities | Corporate obligations | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 276 | 1,060 |
Short-term investments | 1,535 | 1,070 |
Long-term Investments | 0 | 0 |
Measured at fair value | Available-for-sale debt securities | U.S. government and agency securities | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 680 | 642 |
Short-term investments | 4,234 | 3,388 |
Long-term Investments | 0 | 0 |
Measured at fair value | Available-for-sale debt securities | Non-U.S. government and agency securities | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 149 | 300 |
Short-term investments | 248 | 650 |
Long-term Investments | 0 | 0 |
Measured at fair value | Available-for-sale debt securities | Mutual funds | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 0 | 0 |
Long-term Investments | 11 | 16 |
Other measurement basis | Equity-method investments | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 0 | 0 |
Long-term Investments | 18 | 42 |
Other measurement basis | Non-marketable equity investments | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 0 | 0 |
Long-term Investments | 5 | 4 |
Other measurement basis | Cash on hand | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | 707 | 805 |
Short-term investments | 0 | 0 |
Long-term Investments | $ 0 | $ 0 |
Valuation of Debt and Equity _4
Valuation of Debt and Equity Investments and Certain Liabilities - Additional Information (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |||
Credit losses related to available-for-sale investments | $ 0 | $ 0 | $ 0 |
Proceeds from sales, redemptions and maturities of short-term available-for-sale securities | 13,660,000,000 | 8,480,000,000 | 5,290,000,000 |
Proceeds from sale of short-term investments | $ 253,000,000 | ||
Level 3 | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Total assets fair value | 0 | 0 | |
Total liabilities fair value | $ 0 | $ 0 |
Valuation of Debt and Equity _5
Valuation of Debt and Equity Investments and Certain Liabilities - Aggregate Maturities of Available-for-sale Debt Investments (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Fair Value Disclosures [Abstract] | |
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $ 7,049 |
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Two Years | $ 73 |
Valuation of Debt and Equity _6
Valuation of Debt and Equity Investments and Certain Liabilities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | $ 8,371 | $ 8,950 |
Liabilities, fair value | 326 | 395 |
Deferred compensation | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities, fair value | 326 | 395 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 6,163 | 5,469 |
Liabilities, fair value | 326 | 395 |
Level 1 | Deferred compensation | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities, fair value | 326 | 395 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 2,208 | 3,481 |
Liabilities, fair value | 0 | 0 |
Level 2 | Deferred compensation | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liabilities, fair value | 0 | 0 |
Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,238 | 1,824 |
Money market funds | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,238 | 1,824 |
Money market funds | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 0 | 0 |
Corporate obligations | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,811 | 2,130 |
Corporate obligations | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 0 | 0 |
Corporate obligations | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,811 | 2,130 |
U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 4,914 | 4,030 |
U.S. government and agency securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 4,914 | 3,629 |
U.S. government and agency securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 0 | 401 |
Non-U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 397 | 950 |
Non-U.S. government and agency securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 0 | 0 |
Non-U.S. government and agency securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 397 | 950 |
Mutual funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 11 | 16 |
Mutual funds | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 11 | 16 |
Mutual funds | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | $ 0 | $ 0 |
Postretirement Benefit Plans -
Postretirement Benefit Plans - Additional Information (Details) - USD ($) shares in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Defined benefit pension plan formula, highest consecutive years of compensation (in years) | 5 years | ||
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] | Other income (expense), net (OI&E) | Other income (expense), net (OI&E) | Other income (expense), net (OI&E) |
Length of time certain gains and losses are considered when determining the market-related value of assets related to the U.S. Qualified pension and retiree health care plans (in years) | 3 years | ||
Expected contribution to retirement benefit plans in next fiscal year | $ 10,000,000 | ||
Liability to participants of the deferred compensation plan | 326,000,000 | ||
Deferred compensation plan assets | 11,000,000 | ||
Defined Benefit | Equity investments | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Defined benefit plan assets directly invested in TI common stock | 0 | ||
Retiree Health Care | Equity investments | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Defined benefit plan assets directly invested in TI common stock | $ 0 | ||
U.S. | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Number of company shares held by the U.S. defined contribution plans at year-end (in shares) | 6 | 6 | |
Value of the company shares held by the U.S. defined contribution plans at year-end | $ 940,000,000 | $ 1,160,000,000 | |
Dividends paid on the company shares held by the U.S. defined contribution plans at year-end | 28,000,000 | 27,000,000 | |
Aggregate expense for the U.S. defined contribution plans | 70,000,000 | 63,000,000 | $ 61,000,000 |
U.S. | Defined Benefit | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Accumulated benefit obligation | 489,000,000 | 820,000,000 | |
Non-U.S. | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Value of the company shares held by the non-U.S. retirement plans at year-end | 33,000,000 | 38,000,000 | |
Non-U.S. | Defined Benefit | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Accumulated benefit obligation | $ 1,600,000,000 | $ 2,470,000,000 | |
Defined contribution plan, also still accruing defined benefits | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Defined contribution plan, employer matching contribution (percent) | 2% | ||
Enhanced defined contribution plan | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
Defined contribution plan, employer matching contribution (percent) | 4% | ||
Defined contribution plan, employer fixed contribution (percent) | 2% |
Postretirement Benefit Plans _2
Postretirement Benefit Plans - Expense Related to Defined Benefit and Retiree Health Care Benefit Plans (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
U.S. | Defined Benefit | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | $ 15 | $ 21 | $ 18 |
Interest cost | 29 | 30 | 31 |
Expected return on plan assets | (27) | (31) | (36) |
Amortization of prior service cost (credit) | 0 | 0 | 0 |
Recognized net actuarial loss | 3 | 15 | 7 |
Net periodic benefit costs | 20 | 35 | 20 |
Settlement losses | 64 | 13 | 16 |
Total, including other postretirement losses | 84 | 48 | 36 |
U.S. | Retiree Health Care | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | 3 | 3 | 3 |
Interest cost | 11 | 10 | 13 |
Expected return on plan assets | (12) | (9) | (12) |
Amortization of prior service cost (credit) | (2) | (2) | (2) |
Recognized net actuarial loss | 0 | 0 | 0 |
Net periodic benefit costs | 0 | 2 | 2 |
Settlement losses | 0 | 0 | 0 |
Total, including other postretirement losses | 0 | 2 | 2 |
Non-U.S. | Defined Benefit | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | 25 | 36 | 34 |
Interest cost | 33 | 37 | 38 |
Expected return on plan assets | (66) | (81) | (78) |
Amortization of prior service cost (credit) | 1 | 1 | 1 |
Recognized net actuarial loss | 1 | 7 | 14 |
Net periodic benefit costs | (6) | 0 | 9 |
Settlement losses | 10 | 2 | 1 |
Total, including other postretirement losses | $ 4 | $ 2 | $ 10 |
Postretirement Benefit Plans _3
Postretirement Benefit Plans - Benefit Obligations and Plan Assets (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Change in plan assets | |||
Funded status at end of year | $ 61 | $ 303 | |
U.S. | Defined Benefit | |||
Change in plan benefit obligation | |||
Benefit obligation at beginning of year: | 895 | 1,097 | |
Service cost | 15 | 21 | $ 18 |
Interest cost | 29 | 30 | 31 |
Participant contributions | 0 | 0 | |
Benefits paid | (12) | (12) | |
Settlements | (309) | (162) | |
Curtailments | 0 | 0 | |
Actuarial loss (gain) | (97) | (79) | |
Effects of exchange rate changes | 0 | 0 | |
Benefit obligation at end of year | 521 | 895 | 1,097 |
Change in plan assets | |||
Fair value of plan assets at beginning of year: | 934 | 1,061 | |
Actual return on plan assets | (205) | 37 | |
Participant contributions | 0 | 0 | |
Benefits paid | (12) | (12) | |
Settlements | (309) | (162) | |
Effects of exchange rate changes | 0 | 0 | |
Fair value of plan assets at end of year | 421 | 934 | 1,061 |
Funded status at end of year | (100) | 39 | |
U.S. | Defined Benefit | Qualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 0 | 0 | |
U.S. | Defined Benefit | Nonqualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 13 | 10 | |
U.S. | Retiree Health Care | |||
Change in plan benefit obligation | |||
Benefit obligation at beginning of year: | 360 | 389 | |
Service cost | 3 | 3 | 3 |
Interest cost | 11 | 10 | 13 |
Participant contributions | 15 | 14 | |
Benefits paid | (41) | (38) | |
Settlements | 0 | 0 | |
Curtailments | 0 | 0 | |
Actuarial loss (gain) | (74) | (18) | |
Effects of exchange rate changes | 0 | 0 | |
Benefit obligation at end of year | 274 | 360 | 389 |
Change in plan assets | |||
Fair value of plan assets at beginning of year: | 385 | 389 | |
Actual return on plan assets | (80) | 19 | |
Participant contributions | 15 | 14 | |
Benefits paid | (41) | (38) | |
Settlements | 0 | 0 | |
Effects of exchange rate changes | 0 | 0 | |
Fair value of plan assets at end of year | 280 | 385 | 389 |
Funded status at end of year | 6 | 25 | |
U.S. | Retiree Health Care | Qualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 1 | 1 | |
U.S. | Retiree Health Care | Nonqualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 0 | 0 | |
Non-U.S. | Defined Benefit | |||
Change in plan benefit obligation | |||
Benefit obligation at beginning of year: | 2,574 | 2,868 | |
Service cost | 25 | 36 | 34 |
Interest cost | 33 | 37 | 38 |
Participant contributions | 5 | 9 | |
Benefits paid | (86) | (101) | |
Settlements | (91) | (12) | |
Curtailments | (4) | 0 | |
Actuarial loss (gain) | (547) | (111) | |
Effects of exchange rate changes | (242) | (152) | |
Benefit obligation at end of year | 1,667 | 2,574 | 2,868 |
Change in plan assets | |||
Fair value of plan assets at beginning of year: | 2,813 | 3,008 | |
Actual return on plan assets | (557) | 75 | |
Participant contributions | 5 | 9 | |
Benefits paid | (86) | (101) | |
Settlements | (91) | (12) | |
Effects of exchange rate changes | (271) | (173) | |
Fair value of plan assets at end of year | 1,822 | 2,813 | $ 3,008 |
Funded status at end of year | 155 | 239 | |
Non-U.S. | Defined Benefit | Qualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 9 | 7 | |
Non-U.S. | Defined Benefit | Nonqualified Plan | |||
Change in plan assets | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 0 | $ 0 |
Postretirement Benefit Plans _4
Postretirement Benefit Plans - Amounts Recognized on our Balance Sheet (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Defined Benefit Plan Disclosure [Line Items] | ||
Overfunded retirement plans | $ 188 | $ 392 |
Accrued expenses and other liabilities & other long-term liabilities | (9) | (10) |
Underfunded retirement plans | (118) | (79) |
Funded status at end of year | 61 | 303 |
U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Overfunded retirement plans | 0 | 73 |
Accrued expenses and other liabilities & other long-term liabilities | (3) | (5) |
Underfunded retirement plans | (97) | (29) |
Funded status at end of year | (100) | 39 |
U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Overfunded retirement plans | 8 | 28 |
Accrued expenses and other liabilities & other long-term liabilities | 0 | 0 |
Underfunded retirement plans | (2) | (3) |
Funded status at end of year | 6 | 25 |
Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Overfunded retirement plans | 180 | 291 |
Accrued expenses and other liabilities & other long-term liabilities | (6) | (5) |
Underfunded retirement plans | (19) | (47) |
Funded status at end of year | $ 155 | $ 239 |
Postretirement Benefit Plans _5
Postretirement Benefit Plans - Schedule of Change in AOCI (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
Defined benefit plan amounts recognized in other comprehensive income net actuarial loss portion roll forward | |
AOCI balance, net actuarial loss portion (net of taxes), beginning of period | $ 155 |
Adjustments, net actuarial loss | 203 |
Recognized within net income, net actuarial loss | (78) |
Tax effect, net actuarial loss | (31) |
Total change to AOCI, net actuarial loss | 94 |
AOCI balance, net actuarial loss portion (net of taxes), period end | 249 |
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Prior Service Costs Portion Roll Forward | |
AOCI balance, net prior service cost (net of taxes), beginning of period | 0 |
Adjustments, prior service cost | 0 |
Recognized within net income, prior service cost | 1 |
Tax effect, prior service cost | 0 |
Total change to AOCI, prior service credit | 1 |
AOCI balance, net prior service cost (net of taxes), period end | 1 |
U.S. | Defined Benefit | |
Defined benefit plan amounts recognized in other comprehensive income net actuarial loss portion roll forward | |
AOCI balance, net actuarial loss portion (net of taxes), beginning of period | 36 |
Adjustments, net actuarial loss | 137 |
Recognized within net income, net actuarial loss | (67) |
Tax effect, net actuarial loss | (16) |
Total change to AOCI, net actuarial loss | 54 |
AOCI balance, net actuarial loss portion (net of taxes), period end | 90 |
U.S. | Retiree Health Care | |
Defined benefit plan amounts recognized in other comprehensive income net actuarial loss portion roll forward | |
AOCI balance, net actuarial loss portion (net of taxes), beginning of period | (30) |
Adjustments, net actuarial loss | 18 |
Recognized within net income, net actuarial loss | 0 |
Tax effect, net actuarial loss | (3) |
Total change to AOCI, net actuarial loss | 15 |
AOCI balance, net actuarial loss portion (net of taxes), period end | (15) |
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Prior Service Costs Portion Roll Forward | |
AOCI balance, net prior service cost (net of taxes), beginning of period | (1) |
Adjustments, prior service cost | 0 |
Recognized within net income, prior service cost | 2 |
Tax effect, prior service cost | (1) |
Total change to AOCI, prior service credit | 1 |
AOCI balance, net prior service cost (net of taxes), period end | 0 |
Non-U.S. | Defined Benefit | |
Defined benefit plan amounts recognized in other comprehensive income net actuarial loss portion roll forward | |
AOCI balance, net actuarial loss portion (net of taxes), beginning of period | 149 |
Adjustments, net actuarial loss | 48 |
Recognized within net income, net actuarial loss | (11) |
Tax effect, net actuarial loss | (12) |
Total change to AOCI, net actuarial loss | 25 |
AOCI balance, net actuarial loss portion (net of taxes), period end | 174 |
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Prior Service Costs Portion Roll Forward | |
AOCI balance, net prior service cost (net of taxes), beginning of period | 1 |
Adjustments, prior service cost | 0 |
Recognized within net income, prior service cost | (1) |
Tax effect, prior service cost | 1 |
Total change to AOCI, prior service credit | 0 |
AOCI balance, net prior service cost (net of taxes), period end | $ 1 |
Postretirement Benefit Plans _6
Postretirement Benefit Plans - Plan Assets by Level Three Hierarchy (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 421 | $ 934 | $ 1,061 | |
U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 280 | 385 | 389 | |
Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,822 | 2,813 | $ 3,008 | |
Other | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 421 | 934 | |
Other | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 273 | 375 | |
Other | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 1,669 | 2,587 | |
Level 1 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Level 1 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 7 | 10 | ||
Level 1 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 92 | 120 | ||
Level 2 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Level 2 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Level 2 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 61 | 106 | ||
Fixed income securities and cash equivalents | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 272 | 655 | ||
Fixed income securities and cash equivalents | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 182 | 248 | ||
Fixed income securities and cash equivalents | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,382 | 2,220 | ||
Fixed income securities and cash equivalents | Other | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 272 | 655 | |
Fixed income securities and cash equivalents | Other | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 175 | 238 | |
Fixed income securities and cash equivalents | Other | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 1,282 | 2,045 | |
Fixed income securities and cash equivalents | Level 1 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed income securities and cash equivalents | Level 1 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 7 | 10 | ||
Fixed income securities and cash equivalents | Level 1 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 40 | 71 | ||
Fixed income securities and cash equivalents | Level 2 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed income securities and cash equivalents | Level 2 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed income securities and cash equivalents | Level 2 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 60 | 104 | ||
Equity securities | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 149 | 279 | ||
Equity securities | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 98 | 137 | ||
Equity securities | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 440 | 593 | ||
Equity securities | Other | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 149 | 279 | |
Equity securities | Other | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 98 | 137 | |
Equity securities | Other | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | [1] | 387 | 542 | |
Equity securities | Level 1 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity securities | Level 1 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity securities | Level 1 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 52 | 49 | ||
Equity securities | Level 2 | U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity securities | Level 2 | U.S. | Retiree Health Care | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity securities | Level 2 | Non-U.S. | Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 1 | $ 2 | ||
[1]Consists of bond index and equity index funds, measured at net asset value per share, as well as cash equivalents. |
Postretirement Benefit Plans _7
Postretirement Benefit Plans - Weighted Average Assumptions Used (Details) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
U.S. | Defined Benefit | ||
Weighted average assumptions used to determine benefit obligations: | ||
Discount rate (in percent) | 5.67% | 2.74% |
Long-term pay progression (in percent) | 3.75% | 3.70% |
Weighted average assumptions used to determine net periodic benefit cost: | ||
Discount rate (in percent) | 3.82% | 2.95% |
Long term rate of return on plan assets (in percent) | 3.80% | 3.50% |
Long-term pay progression (in percent) | 3.70% | 3.70% |
U.S. | Retiree Health Care | ||
Weighted average assumptions used to determine benefit obligations: | ||
Discount rate (in percent) | 5.68% | 3.05% |
Weighted average assumptions used to determine net periodic benefit cost: | ||
Discount rate (in percent) | 3.05% | 2.74% |
Long term rate of return on plan assets (in percent) | 3.40% | 3.10% |
Non-U.S. | Defined Benefit | ||
Weighted average assumptions used to determine benefit obligations: | ||
Discount rate (in percent) | 3.45% | 1.57% |
Long-term pay progression (in percent) | 3.03% | 3.15% |
Weighted average assumptions used to determine net periodic benefit cost: | ||
Discount rate (in percent) | 1.57% | 1.31% |
Long term rate of return on plan assets (in percent) | 2.73% | 2.82% |
Long-term pay progression (in percent) | 3.15% | 3.15% |
Postretirement Benefit Plans _8
Postretirement Benefit Plans - Weighted Average Allocations (Details) | Dec. 31, 2022 | Dec. 31, 2021 |
Fixed income securities and cash equivalents | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 65% | 70% |
Fixed income securities and cash equivalents | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 65% | 64% |
Fixed income securities and cash equivalents | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 76% | 79% |
Fixed income securities and cash equivalents | Minimum | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 65% | |
Fixed income securities and cash equivalents | Minimum | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 65% | |
Fixed income securities and cash equivalents | Minimum | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 60% | |
Fixed income securities and cash equivalents | Maximum | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 80% | |
Fixed income securities and cash equivalents | Maximum | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 80% | |
Fixed income securities and cash equivalents | Maximum | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 100% | |
Equity securities | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 35% | 30% |
Equity securities | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 35% | 36% |
Equity securities | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Actual plan asset allocation (in percent) | 24% | 21% |
Equity securities | Minimum | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 20% | |
Equity securities | Minimum | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 20% | |
Equity securities | Minimum | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 0% | |
Equity securities | Maximum | U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 35% | |
Equity securities | Maximum | U.S. | Retiree Health Care | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 35% | |
Equity securities | Maximum | Non-U.S. | Defined Benefit | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Targeted allocation (in percent) | 40% |
Postretirement Benefit Plans _9
Postretirement Benefit Plans - Assumed Future Benefits Payments (Details) $ in Millions | Dec. 31, 2022 USD ($) |
U.S. | Defined Benefit | |
Defined Benefit Plan Disclosure [Line Items] | |
2023 | $ 77 |
2024 | 75 |
2025 | 65 |
2026 | 63 |
2027 | 60 |
2028 - 2032 | 227 |
U.S. | Retiree Health Care | |
Defined Benefit Plan Disclosure [Line Items] | |
2023 | 28 |
2024 | 27 |
2025 | 26 |
2026 | 25 |
2027 | 24 |
2028 - 2032 | 106 |
Non-U.S. | Defined Benefit | |
Defined Benefit Plan Disclosure [Line Items] | |
2023 | 84 |
2024 | 87 |
2025 | 89 |
2026 | 91 |
2027 | 92 |
2028 - 2032 | $ 487 |
Postretirement Benefit Plans_10
Postretirement Benefit Plans - Health Care Cost Trend Rates (Details) - U.S. - Retiree Health Care | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | ||
Assumed health care cost trend rate for next year (in percent) | 7% | 6.50% |
Ultimate trend rate (in percent) | 5% | 5% |
Year in which ultimate trend rate is reached | 2031 | 2028 |
Debt and Lines of Credit - Addi
Debt and Lines of Credit - Additional Information (Details) | 1 Months Ended | 12 Months Ended | |||||||||
Nov. 30, 2022 USD ($) seriesOfDebt | Aug. 31, 2022 USD ($) seriesOfDebt | Apr. 30, 2022 USD ($) | Feb. 28, 2021 USD ($) | May 31, 2020 USD ($) | Apr. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Sep. 30, 2021 USD ($) seriesOfDebt | |
Debt Instrument [Line Items] | |||||||||||
Commercial paper | $ 0 | ||||||||||
Repayments of debt | 500,000,000 | $ 550,000,000 | $ 500,000,000 | ||||||||
Proceeds from issuance of long-term debt | 1,494,000,000 | 1,495,000,000 | 1,498,000,000 | ||||||||
Interest and debt expense | 214,000,000 | 184,000,000 | 190,000,000 | ||||||||
Interest paid | $ 198,000,000 | $ 181,000,000 | $ 182,000,000 | ||||||||
Notes due 2032 at 3.65% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 3.65% | ||||||||||
Notes due 2052 at 4.10% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 4.10% | ||||||||||
Notes due 2024 at 4.70% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 4.70% | ||||||||||
Notes due 2028 at 4.60% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 4.60% | ||||||||||
Notes due 2021 at 2.75% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Repayments of debt | $ 550,000,000 | ||||||||||
Notes due 2026 at 1.125% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 1.125% | ||||||||||
Notes due 2031 at 1.90% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 1.90% | ||||||||||
Notes due 2051 at 2.70% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Long-term debt stated interest rate (in percentage) | 2.70% | ||||||||||
Notes due 2025 at 1.375% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 750,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 1.375% | ||||||||||
Payments of debt issuance costs | 4,000,000 | ||||||||||
Proceeds from issuance of long-term debt | $ 749,000,000 | ||||||||||
Notes due 2020 at 1.75% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Repayments of debt | $ 500,000,000 | ||||||||||
Notes due 2030 at 1.75% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 750,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 1.75% | ||||||||||
Payments of debt issuance costs | 5,000,000 | ||||||||||
Proceeds from issuance of long-term debt | $ 749,000,000 | ||||||||||
Notes due 2022 at 1.85% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Repayments of debt | $ 500,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 1.85% | ||||||||||
Senior Notes | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Number of series of debt issued | seriesOfDebt | 2 | 2 | 3 | ||||||||
Principal amount | $ 800,000,000 | $ 700,000,000 | $ 1,500,000,000 | ||||||||
Debt issuance costs | 3,000,000 | 3,000,000 | 10,000,000 | ||||||||
Proceeds from issuance of long-term debt | 799,000,000 | 695,000,000 | |||||||||
Senior Notes | Notes due 2032 at 3.65% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 400,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 3.65% | ||||||||||
Senior Notes | Notes due 2052 at 4.10% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 300,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 4.10% | ||||||||||
Senior Notes | Notes due 2024 at 4.70% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 300,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 4.70% | ||||||||||
Senior Notes | Notes due 2028 at 4.60% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 500,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 4.60% | ||||||||||
Senior Notes | Notes due 2026 at 1.125% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 500,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 1.125% | ||||||||||
Senior Notes | Notes due 2031 at 1.90% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 500,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 1.90% | ||||||||||
Senior Notes | Notes due 2051 at 2.70% | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Principal amount | $ 500,000,000 | ||||||||||
Long-term debt stated interest rate (in percentage) | 2.70% | ||||||||||
Revolving credit facility | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Line of credit facility, maximum borrowing capacity | $ 1,000,000,000 |
Debt and Lines of Credit - Sche
Debt and Lines of Credit - Schedule of Long-term Debt Outstanding (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Debt Instrument [Line Items] | ||
Total debt | $ 8,800 | $ 7,800 |
Net unamortized discounts, premiums and issuance costs | (65) | (59) |
Total debt, including net unamortized discounts, premiums and issuance costs | 8,735 | 7,741 |
Current portion of long-term debt | (500) | (500) |
Long-term debt | $ 8,235 | 7,241 |
Notes due 2022 at 1.85% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 1.85% | |
Total debt | $ 0 | 500 |
Notes due 2023 at 2.25% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 2.25% | |
Total debt | $ 500 | 500 |
Notes due 2024 at 2.625% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 2.625% | |
Total debt | $ 300 | 300 |
Notes due 2024 at 4.70% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 4.70% | |
Total debt | $ 300 | 0 |
Notes due 2025 at 1.375% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 1.375% | |
Total debt | $ 750 | 750 |
Notes due 2026 at 1.125% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 1.125% | |
Total debt | $ 500 | 500 |
Notes due 2027 at 2.90% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 2.90% | |
Total debt | $ 500 | 500 |
Notes due 2028 at 4.60% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 4.60% | |
Total debt | $ 500 | 0 |
Notes due 2029 at 2.25% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 2.25% | |
Total debt | $ 750 | 750 |
Notes due 2030 at 1.75% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 1.75% | |
Total debt | $ 750 | 750 |
Notes due 2031 at 1.90% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 1.90% | |
Total debt | $ 500 | 500 |
Notes due 2032 at 3.65% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 3.65% | |
Total debt | $ 400 | 0 |
Notes due 2039 at 3.875% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 3.875% | |
Total debt | $ 750 | 750 |
Notes due 2048 at 4.15% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 4.15% | |
Total debt | $ 1,500 | 1,500 |
Notes due 2051 at 2.70% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 2.70% | |
Total debt | $ 500 | 500 |
Notes due 2052 at 4.10% | ||
Debt Instrument [Line Items] | ||
Long-term debt stated interest rate (in percentage) | 4.10% | |
Total debt | $ 300 | $ 0 |
Leases - Component of Balance S
Leases - Component of Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Other long-term assets | $ 431 | $ 465 |
Accrued expenses and other liabilities | 75 | 82 |
Operating lease liabilities | $ 344 | $ 383 |
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] | Other long-term assets | Other long-term assets |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] | Accrued expenses and other liabilities | Accrued expenses and other liabilities |
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] | Other long-term liabilities | Other long-term liabilities |
Leases - Schedule of Operating
Leases - Schedule of Operating Leases (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Leases [Abstract] | |||
Lease cost related to lease liabilities | $ 67 | $ 69 | $ 70 |
Variable lease cost | 46 | 56 | 36 |
Cash paid for amounts included in the measurement of lease liabilities: | |||
Operating cash flows for lease cost | 61 | 61 | 59 |
Lease assets obtained in exchange for new lease liabilities | $ 37 | $ 210 | $ 59 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
2023 | $ 81 | |
2024 | 65 | |
2025 | 54 | |
2026 | 48 | |
2027 | 41 | |
Thereafter | 185 | |
Total | 474 | |
Imputed lease interest | (55) | |
Total lease liabilities | $ 419 | |
Weighted average remaining lease term | 8 years 9 months 18 days | 9 years 2 months 12 days |
Weighted average discount rate | 2.71% | 2.51% |
Commitments and Contingencies_2
Commitments and Contingencies (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Purchase Commitments | |
2023 | $ 502 |
2024 | 529 |
2025 | 260 |
2026 | 236 |
2027 | 242 |
Thereafter | 337 |
Total | $ 2,106 |
Supplemental financial inform_3
Supplemental financial information - Restructuring charges and other (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||||||
Oct. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||||
Disclosure Text Block Supplement [Abstract] | ||||||||
Restructuring charges | [1] | $ 0 | $ 0 | $ 25 | ||||
Integration charges | [2] | 257 | 104 | 0 | ||||
Gains on sales of assets | $ (50) | 0 | [3] | (50) | [3] | (1) | [3] | |
Restructuring charges/other | $ 257 | $ 54 | $ 24 | |||||
[1]Includes severance and benefits, changes in estimates and other exit costs.[2]Includes costs related to our purchase of the Lehi, Utah, manufacturing facility, as well as preproduction costs before December 2022.[3]Includes a $50 million gain from the sale of property in October 2021. |
Supplemental financial inform_4
Supplemental financial information - Other income (expense), net (OI&E) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Disclosure Text Block Supplement [Abstract] | ||||
Other income | [1] | $ 168 | $ 145 | $ 327 |
Other expense | [2] | (62) | (2) | (14) |
Total | $ 106 | $ 143 | $ 313 | |
[1]Other income includes interest, royalty and lease income, as well as investment gains and losses and reversals of tax interest accruals.[2] Other expense includes a portion of pension and other retiree benefit costs, currency gains and losses and miscellaneous items. |
Supplemental financial inform_5
Supplemental financial information - Property, plant and equipment at cost (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost | $ 9,950 | $ 7,858 |
Land | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost | 132 | 132 |
Buildings and improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost | $ 4,154 | 3,490 |
Buildings and improvements | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost, depreciable lives | 5 years | |
Buildings and improvements | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost, depreciable lives | 40 years | |
Machinery and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost | $ 5,664 | $ 4,236 |
Machinery and equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost, depreciable lives | 2 years | |
Machinery and equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment at cost, depreciable lives | 10 years |
Supplemental financial inform_6
Supplemental financial information - Schedule of Goodwill (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill [Line Items] | |||
Goodwill | $ 4,362 | $ 4,362 | |
Goodwill impairment loss | 0 | 0 | $ 0 |
Analog | |||
Goodwill [Line Items] | |||
Goodwill | 4,158 | 4,158 | |
Embedded Processing | |||
Goodwill [Line Items] | |||
Goodwill | 172 | 172 | |
Other | |||
Goodwill [Line Items] | |||
Goodwill | $ 32 | $ 32 |
Supplemental financial inform_7
Supplemental financial information - Accrued expenses (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Disclosure Text Block Supplement [Abstract] | ||
Accrued construction retainage | $ 149 | $ 82 |
Other | 497 | 520 |
Total | $ 646 | $ 602 |
Supplemental financial inform_8
Supplemental financial information - Other long-term liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Disclosure Text Block Supplement [Abstract] | ||
Operating lease liabilities | $ 344 | $ 383 |
Deferred compensation plans | 326 | 395 |
Long-term portion of transition tax on indefinitely reinvested earnings | 302 | 403 |
Other | 254 | 186 |
Total | $ 1,226 | $ 1,367 |
Supplemental financial inform_9
Supplemental financial information - Accumulated other comprehensive income (loss), net of taxes (AOCI) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | $ 14,577 | $ 13,333 | ||
AOCI | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | (254) | (157) | $ (360) | $ (347) |
Net actuarial loss | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | (249) | (155) | ||
Prior service cost | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | (1) | 0 | ||
Unrealized losses on available-for-sale investments | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | (3) | 0 | ||
Derivative instruments | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total | $ (1) | $ (2) |
Supplemental financial infor_10
Supplemental financial information - Amounts reclassified out of accumulated other comprehensive income (loss), net of taxes, to net income (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income (expense), net (OI&E) | $ 106 | $ 143 | $ 313 | |
Provision for income taxes | (1,283) | (1,150) | (422) | |
Net income | 8,749 | 7,769 | 5,595 | |
Reclassification out of Accumulated Other Comprehensive Income | Net actuarial losses of defined benefit plans: | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income (expense), net (OI&E) | [1] | 78 | 37 | 38 |
Provision for income taxes | (17) | (8) | (9) | |
Net income | 61 | 29 | 29 | |
Reclassification out of Accumulated Other Comprehensive Income | Prior service cost of defined benefit plans: | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income (expense), net (OI&E) | [1] | (1) | (1) | (1) |
Provision for income taxes | 0 | 0 | 0 | |
Net income | $ (1) | $ (1) | $ (1) | |
[1]Detailed in Note 7 |